<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.7.31">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">


<title>Rektumkarzinom – MTRA</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
  vertical-align: middle;
}
/* CSS for citations */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging-indent div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}</style>


<script src="site_libs/quarto-nav/quarto-nav.js"></script>
<script src="site_libs/quarto-nav/headroom.min.js"></script>
<script src="site_libs/clipboard/clipboard.min.js"></script>
<script src="site_libs/quarto-search/autocomplete.umd.js"></script>
<script src="site_libs/quarto-search/fuse.min.js"></script>
<script src="site_libs/quarto-search/quarto-search.js"></script>
<meta name="quarto:offset" content="./">
<script src="site_libs/quarto-html/quarto.js" type="module"></script>
<script src="site_libs/quarto-html/tabsets/tabsets.js" type="module"></script>
<script src="site_libs/quarto-html/popper.min.js"></script>
<script src="site_libs/quarto-html/tippy.umd.min.js"></script>
<script src="site_libs/quarto-html/anchor.min.js"></script>
<link href="site_libs/quarto-html/tippy.css" rel="stylesheet">
<link href="site_libs/quarto-html/quarto-syntax-highlighting-e1a5c8363afafaef2c763b6775fbf3ca.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="site_libs/bootstrap/bootstrap.min.js"></script>
<link href="site_libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="site_libs/bootstrap/bootstrap-2d2c3c1dc8fcebd689918bbad00a5354.min.css" rel="stylesheet" append-hash="true" id="quarto-bootstrap" data-mode="light">
<script id="quarto-search-options" type="application/json">{
  "location": "navbar",
  "copy-button": false,
  "collapse-after": 3,
  "panel-placement": "end",
  "type": "overlay",
  "limit": 50,
  "keyboard-shortcut": [
    "f",
    "/",
    "s"
  ],
  "show-item-context": false,
  "language": {
    "search-no-results-text": "No results",
    "search-matching-documents-text": "matching documents",
    "search-copy-link-title": "Copy link to search",
    "search-hide-matches-text": "Hide additional matches",
    "search-more-match-text": "more match in this document",
    "search-more-matches-text": "more matches in this document",
    "search-clear-button-title": "Clear",
    "search-text-placeholder": "",
    "search-detached-cancel-button-title": "Cancel",
    "search-submit-button-title": "Submit",
    "search-label": "Search"
  }
}</script>


<link rel="stylesheet" href="styles.css">
</head>

<body class="nav-fixed quarto-light">

<div id="quarto-search-results"></div>
  <header id="quarto-header" class="headroom fixed-top">
    <nav class="navbar navbar-expand-lg " data-bs-theme="dark">
      <div class="navbar-container container-fluid">
      <div class="navbar-brand-container mx-auto">
    <a class="navbar-brand" href="./index.html">
    <span class="navbar-title">MTRA</span>
    </a>
  </div>
            <div id="quarto-search" class="" title="Search"></div>
          <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbarCollapse" aria-controls="navbarCollapse" role="menu" aria-expanded="false" aria-label="Toggle navigation" onclick="if (window.quartoToggleHeadroom) { window.quartoToggleHeadroom(); }">
  <span class="navbar-toggler-icon"></span>
</button>
          <div class="collapse navbar-collapse" id="navbarCollapse">
            <ul class="navbar-nav navbar-nav-scroll me-auto">
  <li class="nav-item">
    <a class="nav-link" href="./index.html"> 
<span class="menu-text">Home</span></a>
  </li>  
  <li class="nav-item">
    <a class="nav-link" href="./about.html"> 
<span class="menu-text">About</span></a>
  </li>  
</ul>
          </div> <!-- /navcollapse -->
            <div class="quarto-navbar-tools">
</div>
      </div> <!-- /container-fluid -->
    </nav>
</header>
<!-- content -->
<div id="quarto-content" class="quarto-container page-columns page-rows-contents page-layout-article page-navbar">
<!-- sidebar -->
<!-- margin-sidebar -->
    <div id="quarto-margin-sidebar" class="sidebar margin-sidebar">
        <nav id="TOC" role="doc-toc" class="toc-active">
    <h2 id="toc-title">On this page</h2>
   
  <ul>
  <li><a href="#kurzüberblick" id="toc-kurzüberblick" class="nav-link active" data-scroll-target="#kurzüberblick">Kurzüberblick</a>
  <ul class="collapse">
  <li><a href="#adjuvante-therapie" id="toc-adjuvante-therapie" class="nav-link" data-scroll-target="#adjuvante-therapie">Adjuvante Therapie</a></li>
  <li><a href="#neoadjuvante-radiochemothearpie" id="toc-neoadjuvante-radiochemothearpie" class="nav-link" data-scroll-target="#neoadjuvante-radiochemothearpie">Neoadjuvante Radiochemothearpie</a></li>
  <li><a href="#chemotherapie" id="toc-chemotherapie" class="nav-link" data-scroll-target="#chemotherapie">Chemotherapie</a></li>
  <li><a href="#totale-neoadjuvante-therapie-tnt" id="toc-totale-neoadjuvante-therapie-tnt" class="nav-link" data-scroll-target="#totale-neoadjuvante-therapie-tnt">Totale neoadjuvante Therapie (TNT)</a></li>
  <li><a href="#aktuell-immuntherapie" id="toc-aktuell-immuntherapie" class="nav-link" data-scroll-target="#aktuell-immuntherapie">Aktuell: Immuntherapie</a></li>
  </ul></li>
  <li><a href="#spreechstunde" id="toc-spreechstunde" class="nav-link" data-scroll-target="#spreechstunde">Spreechstunde</a>
  <ul class="collapse">
  <li><a href="#dokumentation-des-leistungsstatus" id="toc-dokumentation-des-leistungsstatus" class="nav-link" data-scroll-target="#dokumentation-des-leistungsstatus">Dokumentation des Leistungsstatus</a></li>
  <li><a href="#obligatorische-untersuchungen" id="toc-obligatorische-untersuchungen" class="nav-link" data-scroll-target="#obligatorische-untersuchungen">Obligatorische Untersuchungen</a>
  <ul class="collapse">
  <li><a href="#dpd-test" id="toc-dpd-test" class="nav-link" data-scroll-target="#dpd-test">DPD Test</a></li>
  <li><a href="#starre-rektoskopie" id="toc-starre-rektoskopie" class="nav-link" data-scroll-target="#starre-rektoskopie">Starre Rektoskopie</a></li>
  <li><a href="#mrt" id="toc-mrt" class="nav-link" data-scroll-target="#mrt">MRT</a></li>
  <li><a href="#endosonographie" id="toc-endosonographie" class="nav-link" data-scroll-target="#endosonographie">Endosonographie</a></li>
  <li><a href="#cea" id="toc-cea" class="nav-link" data-scroll-target="#cea">CEA</a></li>
  <li><a href="#pet-ct" id="toc-pet-ct" class="nav-link" data-scroll-target="#pet-ct">PET-CT</a></li>
  <li><a href="#histologie" id="toc-histologie" class="nav-link" data-scroll-target="#histologie">Histologie</a></li>
  </ul></li>
  <li><a href="#entfernung-vom-analrand" id="toc-entfernung-vom-analrand" class="nav-link" data-scroll-target="#entfernung-vom-analrand">Entfernung vom Analrand</a></li>
  </ul></li>
  <li><a href="#rechtfertigende-indikation" id="toc-rechtfertigende-indikation" class="nav-link" data-scroll-target="#rechtfertigende-indikation">Rechtfertigende Indikation</a>
  <ul class="collapse">
  <li><a href="#stadium-i-ct1-2n0" id="toc-stadium-i-ct1-2n0" class="nav-link" data-scroll-target="#stadium-i-ct1-2n0">Stadium I (cT1-2N0)</a>
  <ul class="collapse">
  <li><a href="#neoadjuvante-vs.-upfront-chirurgie" id="toc-neoadjuvante-vs.-upfront-chirurgie" class="nav-link" data-scroll-target="#neoadjuvante-vs.-upfront-chirurgie">Neoadjuvante vs.&nbsp;Upfront-Chirurgie</a></li>
  <li><a href="#tiefsitzenden-t1-n0-high-risk-tumore" id="toc-tiefsitzenden-t1-n0-high-risk-tumore" class="nav-link" data-scroll-target="#tiefsitzenden-t1-n0-high-risk-tumore">Tiefsitzenden T1, N0 high-risk Tumore</a></li>
  </ul></li>
  <li><a href="#tumoren-des-unteren-und-mittleren-rektumdrittels" id="toc-tumoren-des-unteren-und-mittleren-rektumdrittels" class="nav-link" data-scroll-target="#tumoren-des-unteren-und-mittleren-rektumdrittels">Tumoren des unteren und mittleren Rektumdrittels</a>
  <ul class="collapse">
  <li><a href="#stadium-iiiii-ct34-undoder-cn" id="toc-stadium-iiiii-ct34-undoder-cn" class="nav-link" data-scroll-target="#stadium-iiiii-ct34-undoder-cn">Stadium II/III (cT3/4 und/oder cN+)</a></li>
  </ul></li>
  <li><a href="#tumore-im-oberen-rektumdrittel" id="toc-tumore-im-oberen-rektumdrittel" class="nav-link" data-scroll-target="#tumore-im-oberen-rektumdrittel">Tumore im oberen Rektumdrittel</a></li>
  <li><a href="#therapie-algorithmus-für-die-stadien-i-iii-der-onkopedia-leitlinie-ralf-dieterhofheinzetal2025" id="toc-therapie-algorithmus-für-die-stadien-i-iii-der-onkopedia-leitlinie-ralf-dieterhofheinzetal2025" class="nav-link" data-scroll-target="#therapie-algorithmus-für-die-stadien-i-iii-der-onkopedia-leitlinie-ralf-dieterhofheinzetal2025">Therapie-Algorithmus für die Stadien I-III der Onkopedia Leitlinie:<span class="citation" data-cites="Ralf-DieterHofheinzEtAl2025"><sup>18</sup></span></a></li>
  </ul></li>
  <li><a href="#strahlentherapie-dosiskonzepte" id="toc-strahlentherapie-dosiskonzepte" class="nav-link" data-scroll-target="#strahlentherapie-dosiskonzepte">Strahlentherapie: Dosiskonzepte</a>
  <ul class="collapse">
  <li><a href="#standard-konventionelle-radiochemotherapie-45504-gy" id="toc-standard-konventionelle-radiochemotherapie-45504-gy" class="nav-link" data-scroll-target="#standard-konventionelle-radiochemotherapie-45504-gy">Standard: Konventionelle Radiochemotherapie (45–50,4 Gy)</a></li>
  <li><a href="#außerhalb-eines-tnt-konzeptes" id="toc-außerhalb-eines-tnt-konzeptes" class="nav-link" data-scroll-target="#außerhalb-eines-tnt-konzeptes">Außerhalb eines TNT-Konzeptes</a></li>
  <li><a href="#im-rahmen-eines-tnt-konzeptes" id="toc-im-rahmen-eines-tnt-konzeptes" class="nav-link" data-scroll-target="#im-rahmen-eines-tnt-konzeptes">Im Rahmen eines TNT-Konzeptes</a>
  <ul class="collapse">
  <li><a href="#teil-1-primärbehandlung-25-fraktionen" id="toc-teil-1-primärbehandlung-25-fraktionen" class="nav-link" data-scroll-target="#teil-1-primärbehandlung-25-fraktionen">Teil 1: Primärbehandlung (25 Fraktionen)</a></li>
  <li><a href="#teil-2-boost-5-fraktionen" id="toc-teil-2-boost-5-fraktionen" class="nav-link" data-scroll-target="#teil-2-boost-5-fraktionen">Teil 2: Boost (5 Fraktionen)</a></li>
  </ul></li>
  <li><a href="#alternative-kurzzeit-radiotherapie" id="toc-alternative-kurzzeit-radiotherapie" class="nav-link" data-scroll-target="#alternative-kurzzeit-radiotherapie">Alternative: Kurzzeit-Radiotherapie</a></li>
  </ul></li>
  <li><a href="#gerätearzt" id="toc-gerätearzt" class="nav-link" data-scroll-target="#gerätearzt">Gerätearzt</a>
  <ul class="collapse">
  <li><a href="#wöchentliche-kontrollbesuche" id="toc-wöchentliche-kontrollbesuche" class="nav-link" data-scroll-target="#wöchentliche-kontrollbesuche">Wöchentliche Kontrollbesuche</a>
  <ul class="collapse">
  <li><a href="#erstgespräch-radiochemotherapiw" id="toc-erstgespräch-radiochemotherapiw" class="nav-link" data-scroll-target="#erstgespräch-radiochemotherapiw">Erstgespräch Radiochemotherapiw</a></li>
  </ul></li>
  <li><a href="#zusammenfassung-am-ende-der-behandlung" id="toc-zusammenfassung-am-ende-der-behandlung" class="nav-link" data-scroll-target="#zusammenfassung-am-ende-der-behandlung">Zusammenfassung am Ende der Behandlung</a></li>
  <li><a href="#nebenwirkungen-nach" id="toc-nebenwirkungen-nach" class="nav-link" data-scroll-target="#nebenwirkungen-nach">Nebenwirkungen nach</a></li>
  <li><a href="#bei-gleichzeitige-systemische-therapie" id="toc-bei-gleichzeitige-systemische-therapie" class="nav-link" data-scroll-target="#bei-gleichzeitige-systemische-therapie">Bei gleichzeitige systemische Therapie</a></li>
  </ul></li>
  <li><a href="#nachsorge" id="toc-nachsorge" class="nav-link" data-scroll-target="#nachsorge">Nachsorge</a>
  <ul class="collapse">
  <li><a href="#bewertung-des-ansprechens-auf-die-behandlung" id="toc-bewertung-des-ansprechens-auf-die-behandlung" class="nav-link" data-scroll-target="#bewertung-des-ansprechens-auf-die-behandlung">Bewertung des Ansprechens auf die Behandlung</a></li>
  <li><a href="#cea-bestimmung-in-der-nachsorge" id="toc-cea-bestimmung-in-der-nachsorge" class="nav-link" data-scroll-target="#cea-bestimmung-in-der-nachsorge">CEA Bestimmung in der Nachsorge</a></li>
  </ul></li>
  <li><a href="#wichtige-studien" id="toc-wichtige-studien" class="nav-link" data-scroll-target="#wichtige-studien">Wichtige Studien</a></li>
  <li><a href="#literatur" id="toc-literatur" class="nav-link" data-scroll-target="#literatur">Literatur</a></li>
  </ul>
</nav>
    </div>
<!-- main -->
<main class="content" id="quarto-document-content">

<header id="title-block-header" class="quarto-title-block default">
<div class="quarto-title">
<h1 class="title">Rektumkarzinom</h1>
</div>



<div class="quarto-title-meta">

    
  
    
  </div>
  


</header>


<section id="kurzüberblick" class="level1">
<h1>Kurzüberblick</h1>
<p><strong>ICD10: C20</strong></p>
<p>Rektumkarzinome sind Tumoren, deren aboraler Rand bei der Messung mit dem starren Rektoskop <strong>16 cm oder weniger</strong> von der <strong>Anokutanlinie</strong> entfernt sind (USA &gt;12cm ab ano = Kolonkarzinome).<span class="citation" data-cites="DeutscheKrebsgesellschaftEtAl2019"><sup><a href="#ref-DeutscheKrebsgesellschaftEtAl2019" role="doc-biblioref">1</a></sup></span></p>
<p>Einst als unheilbare Krankheit angesehen, hat sich die Sterblichkeitsrate bei lokal fortgeschrittenem Rektumkarzinom durch die multimodale Therapie von 100 % auf weniger als 4 % verbessert.<span class="citation" data-cites="GallerEtAl2011"><sup><a href="#ref-GallerEtAl2011" role="doc-biblioref">2</a></sup></span></p>
<p>1982 führte Heald die totale mesorektale Exzision (TME) ein, bei der das gesamte Mesorektum entfernt wird<span class="citation" data-cites="HealdRyall1986"><sup><a href="#ref-HealdRyall1986" role="doc-biblioref">3</a></sup></span>.</p>
<p>Die TME setzte sich in den folgenden zwei Jahrzehnten international durch und setzte einen neuen chirurgischen Standard<span class="citation" data-cites="DeschnerEtAl2021"><sup><a href="#ref-DeschnerEtAl2021" role="doc-biblioref">4</a></sup></span>.</p>
<section id="adjuvante-therapie" class="level2">
<h2 class="anchored" data-anchor-id="adjuvante-therapie">Adjuvante Therapie</h2>
<p>1985 zeigte die Gastrointestinal Tumor Study Group<span class="citation" data-cites="GastrointestinalTumorStudyGroup1985"><sup><a href="#ref-GastrointestinalTumorStudyGroup1985" role="doc-biblioref">5</a></sup></span> , dass <strong>die adjuvante Therapie</strong> Vorteile bei der lokalen Kontrolle (Rezidivrate/Disease-Free Survival) hatte, insbesondere die <strong>Radiochemotherapie.</strong></p>
<p>Die <strong>adjuvante Therapie</strong> war jedoch mit mehreren theoretischen Nachteilen verbunden: Mikrometastasen werden verzögert behandelt, was das Risiko für Fernmetastasen erhöht. Das Ansprechen des Tumors ist oft geringer, da die Durchblutung im postoperativen Gewebe eingeschränkt ist. Zudem bleibt die Chance auf eine sphinktererhaltende Operation unverändert, da bei adjuvanter Therapie kein Downstaging möglich ist<span class="citation" data-cites="DeschnerEtAl2021"><sup><a href="#ref-DeschnerEtAl2021" role="doc-biblioref">4</a></sup></span>.</p>
</section>
<section id="neoadjuvante-radiochemothearpie" class="level2">
<h2 class="anchored" data-anchor-id="neoadjuvante-radiochemothearpie">Neoadjuvante Radiochemothearpie</h2>
<p>Dementsprechend wurde die Radiochemotherapy als <strong>neoadjuvantes</strong> Konzept untersucht, um die Ergebnisse weiter zu verbessern.</p>
<p>1997 zeigte der “Swedish Rectal Cancer Trial”<span class="citation" data-cites="SwedishRectalCancerTrial1997"><sup><a href="#ref-SwedishRectalCancerTrial1997" role="doc-biblioref">6</a></sup></span>, dass die neoadjuvante RT sowohl die lokale Kontrolle als auch das Gesamtüberleben verbesserte, dies war ein Wendepunkt.</p>
<p>Die deutsche CAO/ARO/AIO-94 Studie<span class="citation" data-cites="SauerEtAl2004"><sup><a href="#ref-SauerEtAl2004" role="doc-biblioref">7</a></sup></span> bestätigte, dass die neoadjuvante CRT der adjuvanten CRT in lokal fortgeschrittenen Fällen überlegen war und sementierte die <strong>neoadjuvante</strong> Radiochemotherapie als Standard.</p>
</section>
<section id="chemotherapie" class="level2">
<h2 class="anchored" data-anchor-id="chemotherapie">Chemotherapie</h2>
<p>Trotz verbesserter lokaler Kontrolle blieb die Fernmetastasierung ein zentrales Problem. Die adjuvante Chemotherapie (z.B. in der CAO/ARO/AIO-94-Studie<span class="citation" data-cites="SauerEtAl2004"><sup><a href="#ref-SauerEtAl2004" role="doc-biblioref">7</a></sup></span> mit 5-FU vier Wochen nach der Operation bzw. nach abgeschlossener CRT.) sollte dem entgegenwirken, doch die geringe Compliance schränkte ihren Nutzen deutlich ein<span class="citation" data-cites="IVEtAl2022"><sup><a href="#ref-IVEtAl2022" role="doc-biblioref">8</a></sup></span>.</p>
</section>
<section id="totale-neoadjuvante-therapie-tnt" class="level2">
<h2 class="anchored" data-anchor-id="totale-neoadjuvante-therapie-tnt">Totale neoadjuvante Therapie (TNT)</h2>
<p>Die Stockholm-III-Studie<span class="citation" data-cites="ErlandssonEtAl2017"><sup><a href="#ref-ErlandssonEtAl2017" role="doc-biblioref">9</a></sup></span> zeigte, dass eine Kurzzeitbestrahlung mit verzögerter Operation ebenso wirksam war wie eine Kurzzeitbestrahlung mit sofortiger Operation- was die Möglichkeit einer zusätzlichen Chemotherapie vor der Operation eröffnete.</p>
<p>Daraus entwickelte sich das Konzept der totalen neoadjuvanten Therapie (TNT)<span class="citation" data-cites="BahadoerEtAl2021 ConroyEtAl2021"><sup><a href="#ref-BahadoerEtAl2021" role="doc-biblioref">10</a>,<a href="#ref-ConroyEtAl2021" role="doc-biblioref">11</a></sup></span>, bei der alle Behandlungen <strong>(Radiochemotherapy und Chemotherapy)</strong> vor der Operation durchgeführt werden.</p>
<p>Die Total neoadjuvante Therapie (TNT) verbessert die Ansprechraten. Bei einigen Patienten mit klinisch oder pathologisch komplette Resmission kann eine Operation sogar vermieden werden – wie etwa in der OPRA-Studie gezeigt wurde<span class="citation" data-cites="Garcia-AguilarEtAl2022"><sup><a href="#ref-Garcia-AguilarEtAl2022" role="doc-biblioref">12</a></sup></span>.</p>
</section>
<section id="aktuell-immuntherapie" class="level2">
<h2 class="anchored" data-anchor-id="aktuell-immuntherapie">Aktuell: Immuntherapie</h2>
<p>Bei MSI-H/dMMR-Tumoren kommt aktuell vorrangig eine Immuntherapie zum Einsatz, die zu kompletter Remission führen soll<span class="citation" data-cites="CercekEtAl2022"><sup><a href="#ref-CercekEtAl2022" role="doc-biblioref">13</a></sup></span>.</p>
</section>
</section>
<section id="spreechstunde" class="level1">
<h1>Spreechstunde</h1>
<section id="dokumentation-des-leistungsstatus" class="level2">
<h2 class="anchored" data-anchor-id="dokumentation-des-leistungsstatus">Dokumentation des Leistungsstatus</h2>
<p>Die Dokumentation des Leistungsstatus erfolgt nach der Einteilung der Eastern Cooperative Oncology Group (ECOG)</p>
</section>
<section id="obligatorische-untersuchungen" class="level2">
<h2 class="anchored" data-anchor-id="obligatorische-untersuchungen">Obligatorische Untersuchungen</h2>
<p>Folgende Untersuchungen laut S3-Leitlinie<span class="citation" data-cites="DeutscheKrebsgesellschaftEtAl2019"><sup><a href="#ref-DeutscheKrebsgesellschaftEtAl2019" role="doc-biblioref">1</a></sup></span> notwendig:</p>
<ul>
<li><p>Rö-Thorax (2 Ebenen)</p>
<ul>
<li>Im Falle eines unklaren Befundes oder des Verdachtes auf Fernmetastasen oder Infiltration von Nachbarorganen oder umgebende Strukturen soll ein Mehrzeilen-CT des Abdomens und Beckens erfolgen bzw:</li>
</ul></li>
<li><p>Bei Verdacht auf Lungenmetastasen ein CT des Thorax</p></li>
<li><p>CEA</p></li>
<li><p>Histologie/ MSI (Mikrosatelliteninstabilität)</p></li>
<li><p>DPD Test</p></li>
<li><p><strong>Anamnese:</strong> Einnahme von Brivudin in der <strong>letzte 4 Wochen</strong>. (Nach Abschluss der Brivudin-Behandlung muss eine mindestens vierwöchige Wartezeit, eingehalten werden, bevor die Behandlung mit einem Fluoropyrimidin begonnen werden kann.)<span class="citation" data-cites="Aerzteblatt2012"><sup><a href="#ref-Aerzteblatt2012" role="doc-biblioref">14</a></sup></span></p></li>
</ul>
<p><strong>CAVE:</strong> Zum Zeitpunkt der Erstdiagnose eines Rektumkarzinoms liegen bei 18% der Patienten Fernmetastasen vor.</p>
<ul>
<li>Leber 15%</li>
<li>Lungen 4%</li>
</ul>
<section id="dpd-test" class="level3">
<h3 class="anchored" data-anchor-id="dpd-test">DPD Test</h3>
<p>Bei Vorliegen eines DPD-Mangels kann das Medikament 5-FU bzw. Capecitabin (Prodrug) nicht verstoffwechselt werden und es kommt zu schweren Toxizitäten. 30 % dieser gefährlichen Reaktionen sind durch einen DPD-Mangel erklärbar. Dementsprechend <strong><em>muss</em></strong> beim Erstgespräch der DPD-Test vorliegen, bzw. wird abgenommen.</p>
<p>Hierbei handelt sich um eine genetische Untersuchung im Sinne des Gendiagnostik-/Gentechnikgesetzes, d.&nbsp;h., es sind bestimmte Vorgaben einzuhalten (Aufklärung, Einwilligung, Durchführung durch einen Arzt und Mitteilung der Ergebnisse).</p>
<p>DPYD-Varianten sind als pharmakogenetische Eigenschaften mit hoher Bedeutung einzuordnen.</p>
<p>Wird eine klinisch relevante DPD-Variante gefunden, ist dem Patienten gemäß §10 Abs.1 Satz2 GenDG eine genetische Beratung anzubieten. Der Patient kann auf eine genetische Beratung nach dem Vorliegen der Testergebnisse verzichten, der Verzicht ist schriftlich zu dokumentieren. Wenn eine genetische Beratung nach dem Vorliegen des Testergebnisses gewünscht wird, darf die Beratung nur durch einen Facharzt für Humangenetik oder einen nach dem GenDG qualifizierten Arzt vorgenommen werden.<span class="citation" data-cites="DGHO2020 2020"><sup><a href="#ref-DGHO2020" role="doc-biblioref">15</a>,<a href="#ref-2020" role="doc-biblioref">16</a></sup></span></p>
</section>
<section id="starre-rektoskopie" class="level3">
<h3 class="anchored" data-anchor-id="starre-rektoskopie">Starre Rektoskopie</h3>
<p>Beim Rektumkarzinom sollte die starre Rektoskopie mit Höhenangabe des Tumorunterrandes obligater Bestandteil der präoperativen Diagnostik sein.<span class="citation" data-cites="DeutscheKrebsgesellschaftEtAl2019"><sup><a href="#ref-DeutscheKrebsgesellschaftEtAl2019" role="doc-biblioref">1</a></sup></span></p>
</section>
<section id="mrt" class="level3">
<h3 class="anchored" data-anchor-id="mrt">MRT</h3>
<p>Die Befundbeschreibung soll eine Aussage über den Abstand zur mesorektalen Faszie beinhalten.<span class="citation" data-cites="DeutscheKrebsgesellschaftEtAl2019"><sup><a href="#ref-DeutscheKrebsgesellschaftEtAl2019" role="doc-biblioref">1</a></sup></span></p>
</section>
<section id="endosonographie" class="level3">
<h3 class="anchored" data-anchor-id="endosonographie">Endosonographie</h3>
<p>Im Falle eines mutmaßlichen T1-Karzinoms eine Endosonographie, hier ist die CT nicht geeignet. Bei der Differenzierung von T2 und T3-Karzinomen wies die Endosonographie wiederum eine höhere Sensitivität im Vergleich zu MRT und CT auf bei vergleichbarer Spezifität. In der Endosonographie lässt sich die mesorektale Faszie nicht darstellen.<span class="citation" data-cites="DeutscheKrebsgesellschaftEtAl2019"><sup><a href="#ref-DeutscheKrebsgesellschaftEtAl2019" role="doc-biblioref">1</a></sup></span></p>
</section>
<section id="cea" class="level3">
<h3 class="anchored" data-anchor-id="cea">CEA</h3>
<p>Bei etwa 30% aller kolorektaler Karzinome ist der Tumormarker CEA zum Zeitpunkt der Erstdiagnose erhöht.</p>
<p>Insbesondere in der Tumornachsorge ist dieser Tumormarker ein zuverlässiger Hinweis auf ein Rezidiv. Als weitere Tumormarker werden CA 19-9 und CA 125 diskutiert, wobei letzterer ein Marker der Peritonealkarzinose ist.</p>
<p>Laut S3-Leitlinie erhöht der CA 19-9 Wert die Aussagefähigkeit bezüglich des Vorliegens eines Rezidivs im Vergleich zu einer alleinigen CEA-Wert-Bestimmung nicht.<span class="citation" data-cites="DeutscheKrebsgesellschaftEtAl2019"><sup><a href="#ref-DeutscheKrebsgesellschaftEtAl2019" role="doc-biblioref">1</a></sup></span></p>
</section>
<section id="pet-ct" class="level3">
<h3 class="anchored" data-anchor-id="pet-ct">PET-CT</h3>
<p>Hat keinen Stellenwert in der Ausbreitungsdiagnostik bei Erstdiagnose eines kolorektalen Karzinoms.<span class="citation" data-cites="DeutscheKrebsgesellschaftEtAl2019"><sup><a href="#ref-DeutscheKrebsgesellschaftEtAl2019" role="doc-biblioref">1</a></sup></span></p>
</section>
<section id="histologie" class="level3">
<h3 class="anchored" data-anchor-id="histologie">Histologie</h3>
<section id="mmrmsi-status" class="level4">
<h4 class="anchored" data-anchor-id="mmrmsi-status">MMR/MSI-Status</h4>
<p>Bei etwa 3-5% der Patienten mit lokal begrenztem Rektumkarzinom ist ein DNS- Mismatch-Reparaturdefekt (dMMR) bzw. eine Mikrosatelliten-Instabilität (MSI-H) in der Tumorbiopsie nachweisbar.</p>
<p>Dostarlimab kann eine klinische komplette Remission erreichen. So dass eine Radiochemotherapie und eine Operation unterbleiben kann. Eine <a href="https://www.dgho.de/publikationen/stellungnahmen/gute-aerztliche-praxis/immuncheckpoint-inhibitoren/immuncheckpointinhibitor-20230508.pdf">Handreichung der DGHO</a> kann bei der Beantragung dieser Therapie hilfreich sein.</p>
</section>
</section>
</section>
<section id="entfernung-vom-analrand" class="level2">
<h2 class="anchored" data-anchor-id="entfernung-vom-analrand">Entfernung vom Analrand</h2>
<p>Die präoperative Messung der Höhenangabe des Tumors mit dem flexiblen Endoskop ist unzuverlässig. Zuverlässiger sind die <strong>Höhenangaben mit dem starren Rektoskop.</strong><span class="citation" data-cites="DeutscheKrebsgesellschaftEtAl2019"><sup><a href="#ref-DeutscheKrebsgesellschaftEtAl2019" role="doc-biblioref">1</a></sup></span> Dementsprechend werden letztere dokumetiert. Ab Anokutanlinie:</p>
<ul>
<li>oberes Rektumdrittels (12 - 16 cm)</li>
<li>mittleres Rektumdrittels (6 - &lt;12 cm)</li>
<li>unteres Rektumdrittels (&lt; 6 cm) unterteilt</li>
</ul>
</section>
</section>
<section id="rechtfertigende-indikation" class="level1">
<h1>Rechtfertigende Indikation</h1>
<p>Die Entscheidung für eine Strahlentherapie in unserer Praxis basiert auf einer <strong>Empfehlung des Tumorboards</strong>.</p>
<p>Dabei muss klar zwischen einem <strong>TNT-Konzept</strong> und einer <strong>neoadjuvanten Radiochemotherapie mit anschließender Operation</strong> unterschieden werden.</p>
<p>Ist diese Unterscheidung in der Empfehlung des Tumorboards nicht eindeutig dokumentiert, muss <strong>vor Therapiebeginn</strong> Rücksprache mit der Onkologie gehalten werden.</p>
<section id="stadium-i-ct1-2n0" class="level2">
<h2 class="anchored" data-anchor-id="stadium-i-ct1-2n0">Stadium I (cT1-2N0)</h2>
<section id="neoadjuvante-vs.-upfront-chirurgie" class="level3">
<h3 class="anchored" data-anchor-id="neoadjuvante-vs.-upfront-chirurgie">Neoadjuvante vs.&nbsp;Upfront-Chirurgie</h3>
<p>Bei T1-High-Risk-Karzinomen (G3/4 u./o. Lymphgefäßinvasion) und bei T2 Karzinomen liegt das Auftreten von Lymphknotenmetastasen bei 10–20%, sodass die alleinige lokale Exzision nicht empfohlen werden kann und eine primäre radikale Operation oder eine sekundäre radikale Nachoperation indiziert sind.</p>
<p>Lehnt der Patient in dieser Situation eine radikale Nachoperation ab, so kann eine <strong>adjuvante Radiochemotherapie</strong> erwogen werden.</p>
<p>Dahingengend haben Rektumkarzinome im UICC-Stadium I (T1/2, N0) nach alleiniger radikaler Operation mit adäquater totaler mesorektaler Exzision (TME) für Tumoren im unteren/mittleren Drittel sowie partieller mesorektaler Exzision (PME) für Tumoren im oberen Rektumdrittel niedrige Lokalrezidiv- und Fernmetastasenraten (3 % Lokalrezidive bzw. weniger als 10 % Fernmetastasen nach 10 Jahren.</p>
<p>Dementsprechend soll bei Tumore in UICC-Stadium I (cT1-2, N0) eine präoperative Therapie nicht durchgeführt werden.<span class="citation" data-cites="DeutscheKrebsgesellschaftEtAl2019"><sup><a href="#ref-DeutscheKrebsgesellschaftEtAl2019" role="doc-biblioref">1</a></sup></span></p>
</section>
<section id="tiefsitzenden-t1-n0-high-risk-tumore" class="level3">
<h3 class="anchored" data-anchor-id="tiefsitzenden-t1-n0-high-risk-tumore">Tiefsitzenden T1, N0 high-risk Tumore</h3>
<p>Für Patienten mit tiefsitzenden T1, N0 high-risk (G3/4, L1, V1, Durchmesser größer 3 cm, sm3) oder T2N0-Tumoren, die eine Exstirpation ablehnen, ist die Radio(chemo-) therapie, gefolgt von lokaler Exzision/transanaler endoskopischer Mikrochirurgie oder einer wait-and-see Strategie bei klinisch kompletter Remission eine Behandlungsoption<span class="citation" data-cites="DeutscheKrebsgesellschaftEtAl2019"><sup><a href="#ref-DeutscheKrebsgesellschaftEtAl2019" role="doc-biblioref">1</a></sup></span></p>
<p>Laut NCCN Leitlinie<span class="citation" data-cites="NationalComprehensiveCancerNetwork2025a"><sup><a href="#ref-NationalComprehensiveCancerNetwork2025a" role="doc-biblioref">17</a></sup></span> können bei hochrisiko cT1–2, N0 Tumore eine Radiochemotherapie mit Capecitabin oder 5-Fluorouracil (5-FU), oder eine Kurzzeit-RT gefolgt von FOLFOX or CAPEOX erfolgen.</p>
<p>Zu den Hochrisikomerkmalen gehören positive Ränder, lymphatische Invasion, schlecht differenzierte Tumore oder sm3-Invasion (submuköse Invasion bis zum unteren Drittel der Submukosa).</p>
</section>
</section>
<section id="tumoren-des-unteren-und-mittleren-rektumdrittels" class="level2">
<h2 class="anchored" data-anchor-id="tumoren-des-unteren-und-mittleren-rektumdrittels">Tumoren des unteren und mittleren Rektumdrittels</h2>
<section id="stadium-iiiii-ct34-undoder-cn" class="level3">
<h3 class="anchored" data-anchor-id="stadium-iiiii-ct34-undoder-cn">Stadium II/III (cT3/4 und/oder cN+)</h3>
<p>Eine neoadjuvante Radiochemotherapie oder KurzzeitRadiotherapie soll erfolgen.<span class="citation" data-cites="DeutscheKrebsgesellschaftEtAl2019"><sup><a href="#ref-DeutscheKrebsgesellschaftEtAl2019" role="doc-biblioref">1</a></sup></span></p>
<p><strong>Ausnahmen<span class="citation" data-cites="DeutscheKrebsgesellschaftEtAl2019"><sup><a href="#ref-DeutscheKrebsgesellschaftEtAl2019" role="doc-biblioref">1</a></sup></span> :</strong></p>
<ul>
<li><p>cT1/2 Tumore im unteren und mittleren Drittel mit bildgebend fraglichen Lymphknotenbefall.</p></li>
<li><p>cT3a/b Tumore im mittleren Drittel mit in der MRT nur limitierter Infiltration ins perirektale Fettgewebe (cT3a: &lt;1 mm, cT3b: 1-5 mm) und ohne bildgebenden Verdacht auf Lymphknotenmetastasen oder extra-muraler Gefäßinvasion (EMVI-) bei adäquater Qualitätssicherung der MRT-Diagnostik und der TME-Chirurgie.</p></li>
</ul>
</section>
</section>
<section id="tumore-im-oberen-rektumdrittel" class="level2">
<h2 class="anchored" data-anchor-id="tumore-im-oberen-rektumdrittel">Tumore im oberen Rektumdrittel</h2>
<p>Rektumkarzinome im oberen Drittel ohne Risikokonstellation für ein Lokal-rezidiv sollen primär operiert. Jedoch eine präoperative Radio-/ Radiochemotherapie <strong><em>kann</em></strong>, Bei einer Risikokonstellation, erfolgen<span class="citation" data-cites="DeutscheKrebsgesellschaftEtAl2019"><sup><a href="#ref-DeutscheKrebsgesellschaftEtAl2019" role="doc-biblioref">1</a></sup></span> z.B.:</p>
<ul>
<li>T4</li>
<li>mrCRM+</li>
<li>bildgebend eindeutiger und ausgedehnter Lymphknotenbefall</li>
</ul>
</section>
<section id="therapie-algorithmus-für-die-stadien-i-iii-der-onkopedia-leitlinie-ralf-dieterhofheinzetal2025" class="level2">
<h2 class="anchored" data-anchor-id="therapie-algorithmus-für-die-stadien-i-iii-der-onkopedia-leitlinie-ralf-dieterhofheinzetal2025">Therapie-Algorithmus für die Stadien I-III der Onkopedia Leitlinie:<span class="citation" data-cites="Ralf-DieterHofheinzEtAl2025"><sup><a href="#ref-Ralf-DieterHofheinzEtAl2025" role="doc-biblioref">18</a></sup></span></h2>
<div class="quarto-figure quarto-figure-center">
<figure class="figure">
<p><img src="Bilder/AlgorithmusOnkopedia.jpg" class="img-fluid figure-img"></p>
<figcaption>cCR - klinische Komplettremission; PME - Partielle Mesorektumexzision; TME - Totale Mesorektumexzision; w/w - watch &amp; wait; TNT - totale neoadjuvante Therapie; RT –Strahlentherapie; RChT – Strahlenchemotherapie; RF – Risikofaktoren; MSI-H – hohe Mikrosatelliteninstabilität; EMVI+ - extramurale Gefäßinvasion; TNT – totale neoadjuvante Therapie; mrCRM+ - positiver präoperativer zirkumferenzieller Resektionsrand im MRT; LK+ - befallene Lymphknoten; Brachy – Brachytherapie</figcaption>
</figure>
</div>
</section>
</section>
<section id="strahlentherapie-dosiskonzepte" class="level1">
<h1>Strahlentherapie: Dosiskonzepte</h1>
<p>Sowohl die Kurzzeitbestrahlung als auch die konventionell fraktionierte Radiochemotherapie haben spezifische Vor- und Nachteile<span class="citation" data-cites="SauerEtAl2004 BahadoerEtAl2021"><sup><a href="#ref-SauerEtAl2004" role="doc-biblioref">7</a>,<a href="#ref-BahadoerEtAl2021" role="doc-biblioref">10</a></sup></span>.</p>
<p>Die Kurzzeitbestrahlung ist schnell und akut gut verträglich, dies ermöglicht eine rasche Operation, lässt jedoch Fragen zur Langzeitwirksamkeit (DFS/OS) und Spättoxizität offen<span class="citation" data-cites="BujkoEtAl2006"><sup><a href="#ref-BujkoEtAl2006" role="doc-biblioref">19</a></sup></span>. Die konventionelle Radiochemotherapie erzielt ein besseres Downstaging, ist aber mit höherer akuter Toxizität verbunden<span class="citation" data-cites="JinEtAl2022"><sup><a href="#ref-JinEtAl2022" role="doc-biblioref">20</a></sup></span>.</p>
<p>Da bisher unklar ist, ob einem der beiden Konzepte deutlich übelegen ist, lässt die aktuelle deutsche S3-Leitlinie beide Optionen gleichwertig zu (Empfehlungsgrad 0)<span class="citation" data-cites="DeutscheKrebsgesellschaftEtAl2019"><sup><a href="#ref-DeutscheKrebsgesellschaftEtAl2019" role="doc-biblioref">1</a></sup></span>:</p>
<p>„Die neoadjuvante Radiotherapie kann entweder als Kurzzeitbestrahlung mit sofortiger Operation oder als konventionell fraktionierte Radiochemotherapie mit einem Intervall von 6–8 Wochen bis zur Operation erfolgen.“</p>
<p>Vor diesem Hintergrund untersucht die multizentrische Studie CAO/ARO/AIO-18.1 unter der Leitung von Prof.&nbsp;Rödel (Frankfurt) diese unterschiedliche Konzepte. Verglichen werden eine Kurzzeitbestrahlung nach dem RAPIDO-Schema<span class="citation" data-cites="BahadoerEtAl2021"><sup><a href="#ref-BahadoerEtAl2021" role="doc-biblioref">10</a></sup></span> und eine konventionelle Radiochemotherapie (CRT) nach dem CAO/ARO/AIO-04/-12-Protokoll<span class="citation" data-cites="FokasEtAl2019"><sup><a href="#ref-FokasEtAl2019" role="doc-biblioref">21</a></sup></span> .</p>
<p>Die Vermutung ist, dass eine CRT mit 5-FU/Oxaliplatin, gefolgt von Konsolidierungschemotherapie, die Organerhaltungsrate verbessert – bei vergleichbarem krankheitsfreiem Überleben (DFS).</p>
<section id="standard-konventionelle-radiochemotherapie-45504-gy" class="level2">
<h2 class="anchored" data-anchor-id="standard-konventionelle-radiochemotherapie-45504-gy">Standard: Konventionelle Radiochemotherapie (45–50,4 Gy)</h2>
<p>Die präoperative Radiochemotherapie ist dafür bekannt, ein effektives Downstaging zu ermöglichen, wodurch die Chance auf Sphinktererhalt steigt und ausgedehntere Operationen vermieden werden können<span class="citation" data-cites="SauerEtAl2004"><sup><a href="#ref-SauerEtAl2004" role="doc-biblioref">7</a></sup></span>.</p>
<p>Zudemn besteht Hinsichtlich der Kurzzeitbestrahlung weiterhin Unsicherheit über mögliche Langzeitmorbiditäten. Einige Studien berichten über langfristige Komplikationen, jedoch fehlen bislang umfassende direkte Vergleiche zur Radiochemotherapie<span class="citation" data-cites="BahadoerEtAl2021"><sup><a href="#ref-BahadoerEtAl2021" role="doc-biblioref">10</a></sup></span>.</p>
<p>Darüberhinaus gilt in Deutschland die konventionelle Radiochemotherapie als Standard. Entsprechend gilt auch in unserer Praxis derzeit die normofraktionierte Bestrahlung im Rahmen einer kombinierten Radiochemotherapie als Standard.</p>
<p>Diese <strong>soll laut S3-Leitlinie</strong> in folgenden Fällen durchgeführt werden<span class="citation" data-cites="DeutscheKrebsgesellschaftEtAl2019"><sup><a href="#ref-DeutscheKrebsgesellschaftEtAl2019" role="doc-biblioref">1</a></sup></span>:</p>
<ul>
<li>T4-Tumoren<br>
</li>
<li>Tumornähe zur mesorektalen Faszie (&lt;1–2 mm)<br>
</li>
<li>Tiefliegende Tumoren mit intendiertem Sphinktererhalt</li>
</ul>
</section>
<section id="außerhalb-eines-tnt-konzeptes" class="level2">
<h2 class="anchored" data-anchor-id="außerhalb-eines-tnt-konzeptes">Außerhalb eines TNT-Konzeptes</h2>
<p>Die Bestrahlung erfolgt in <strong>25 Fraktionen</strong> mit zwei Zielvolumina:</p>
<ul>
<li><strong>Rektum</strong>: 2,0 Gy Einzeldosis<br>
</li>
<li><strong>Pelvines LAG</strong>: 1,8 Gy Einzeldosis</li>
</ul>
</section>
<section id="im-rahmen-eines-tnt-konzeptes" class="level2">
<h2 class="anchored" data-anchor-id="im-rahmen-eines-tnt-konzeptes">Im Rahmen eines TNT-Konzeptes</h2>
<p>Die Therapie wird in <strong>30 Fraktionen</strong> in zwei Abschnitte unterteilt:</p>
<section id="teil-1-primärbehandlung-25-fraktionen" class="level3">
<h3 class="anchored" data-anchor-id="teil-1-primärbehandlung-25-fraktionen">Teil 1: Primärbehandlung (25 Fraktionen)</h3>
<p>Zwei Volumina werden behandelt:</p>
<ul>
<li><strong>Rektum</strong>: 1,8 Gy Einzeldosis<br>
</li>
<li><strong>Pelvines LAG</strong>: 1,8 Gy Einzeldosis</li>
</ul>
</section>
<section id="teil-2-boost-5-fraktionen" class="level3">
<h3 class="anchored" data-anchor-id="teil-2-boost-5-fraktionen">Teil 2: Boost (5 Fraktionen)</h3>
<p>Ein Volumen wird behandelt:</p>
<ul>
<li><strong>Rektum</strong>: 1,8 Gy Einzeldosis</li>
</ul>
</section>
</section>
<section id="alternative-kurzzeit-radiotherapie" class="level2">
<h2 class="anchored" data-anchor-id="alternative-kurzzeit-radiotherapie">Alternative: Kurzzeit-Radiotherapie</h2>
<p>Die Kurzzeitbestrahlung ist geeignet für Patienten, die eine Radiochemotherapie vermutlich nicht tolerieren – z. B. aufgrund von Alter oder Komorbiditäten.</p>
<p>Diese erfolgt analog zur RAPIDO<span class="citation" data-cites="BahadoerEtAl2021"><sup><a href="#ref-BahadoerEtAl2021" role="doc-biblioref">10</a></sup></span> in <strong>5 Fraktionen à 5 Gy</strong></p>
<p>Für Patienten, bei denen ein <strong>Downsizing</strong> angestrebt wird, kann auch die Kurzzeitbestrahlung mit einem längeren Intervall bis zu 12 Wochen bis zur Operation durchgeführt werden – mit oder ohne zusätzlicher neoadjuvanter Chemotherapie.</p>
</section>
</section>
<section id="gerätearzt" class="level1">
<h1>Gerätearzt</h1>
<section id="wöchentliche-kontrollbesuche" class="level2">
<h2 class="anchored" data-anchor-id="wöchentliche-kontrollbesuche">Wöchentliche Kontrollbesuche</h2>
<section id="erstgespräch-radiochemotherapiw" class="level3">
<h3 class="anchored" data-anchor-id="erstgespräch-radiochemotherapiw">Erstgespräch Radiochemotherapiw</h3>
<p>Vor Beginn der Chemotherapie sollten alle Patienten routinemäßig ein Elektrokardiogramm (EKG) und eine Echokardiographie erhalten, da 5-Fluorouracil (5-FU) potenziell kardiotoxisch wirkt und Koronarspasmen auslösen kann.<span class="citation" data-cites="SaraEtAl2018"><sup><a href="#ref-SaraEtAl2018" role="doc-biblioref">22</a></sup></span></p>
<p><strong>Sonder Aufklärung</strong>: Bei einer Behandlung mit 5-Fluorouracil (5-FU) ist die gleichzeitige Gabe von Brivudin (Zostex®) absolut Kontraindiziert. Dies ist wichtig im Falle vom Herpes Zoster (Gürtelrose). Brivudin hemmt das Enzym Dihydropyrimidin-Dehydrogenase (DPD), das für den Abbau von 5-FU essenziell ist. Eine gleichzeitige Einnahme kann daher zu einer Akkumulation von 5-FU im Körper führen und potenziell lebensbedrohliche toxische Nebenwirkungen verursachen.<span class="citation" data-cites="Aerzteblatt2012"><sup><a href="#ref-Aerzteblatt2012" role="doc-biblioref">14</a></sup></span></p>
</section>
</section>
<section id="zusammenfassung-am-ende-der-behandlung" class="level2">
<h2 class="anchored" data-anchor-id="zusammenfassung-am-ende-der-behandlung">Zusammenfassung am Ende der Behandlung</h2>
</section>
<section id="nebenwirkungen-nach" class="level2">
<h2 class="anchored" data-anchor-id="nebenwirkungen-nach">Nebenwirkungen nach</h2>
<div class="cell">
<div class="cell-output-display">
<div id="rczwvfjjqe" style="padding-left:0px;padding-right:0px;padding-top:10px;padding-bottom:10px;overflow-x:auto;overflow-y:auto;width:auto;height:auto;">
<style>@import url("https://fonts.googleapis.com/css2?family=Source+Sans+Pro:ital,wght@0,100;0,200;0,300;0,400;0,500;0,600;0,700;0,800;0,900;1,100;1,200;1,300;1,400;1,500;1,600;1,700;1,800;1,900&display=swap");
@import url("https://fonts.googleapis.com/css2?family=Libre+Franklin:ital,wght@0,100;0,200;0,300;0,400;0,500;0,600;0,700;0,800;0,900;1,100;1,200;1,300;1,400;1,500;1,600;1,700;1,800;1,900&display=swap");
@import url("https://fonts.googleapis.com/css2?family=Source+Sans+Pro:ital,wght@0,100;0,200;0,300;0,400;0,500;0,600;0,700;0,800;0,900;1,100;1,200;1,300;1,400;1,500;1,600;1,700;1,800;1,900&display=swap");
#rczwvfjjqe table {
  font-family: system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji';
  -webkit-font-smoothing: antialiased;
  -moz-osx-font-smoothing: grayscale;
}

#rczwvfjjqe thead, #rczwvfjjqe tbody, #rczwvfjjqe tfoot, #rczwvfjjqe tr, #rczwvfjjqe td, #rczwvfjjqe th {
  border-style: none;
}

#rczwvfjjqe p {
  margin: 0;
  padding: 0;
}

#rczwvfjjqe .gt_table {
  display: table;
  border-collapse: collapse;
  line-height: normal;
  margin-left: auto;
  margin-right: auto;
  color: #333333;
  font-size: 16px;
  font-weight: normal;
  font-style: normal;
  background-color: #FFFFFF;
  width: auto;
  border-top-style: none;
  border-top-width: 2px;
  border-top-color: #A8A8A8;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #A8A8A8;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
}

#rczwvfjjqe .gt_caption {
  padding-top: 4px;
  padding-bottom: 4px;
}

#rczwvfjjqe .gt_title {
  color: #333333;
  font-size: 125%;
  font-weight: initial;
  padding-top: 4px;
  padding-bottom: 4px;
  padding-left: 5px;
  padding-right: 5px;
  border-bottom-color: #FFFFFF;
  border-bottom-width: 0;
}

#rczwvfjjqe .gt_subtitle {
  color: #333333;
  font-size: 85%;
  font-weight: initial;
  padding-top: 3px;
  padding-bottom: 5px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-color: #FFFFFF;
  border-top-width: 0;
}

#rczwvfjjqe .gt_heading {
  background-color: #FFFFFF;
  text-align: left;
  border-bottom-color: #FFFFFF;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#rczwvfjjqe .gt_bottom_border {
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#rczwvfjjqe .gt_col_headings {
  border-top-style: none;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: none;
  border-bottom-width: 1px;
  border-bottom-color: #334422;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#rczwvfjjqe .gt_col_heading {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 12px;
  font-weight: normal;
  text-transform: inherit;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 6px;
  padding-left: 5px;
  padding-right: 5px;
  overflow-x: hidden;
}

#rczwvfjjqe .gt_column_spanner_outer {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 12px;
  font-weight: normal;
  text-transform: inherit;
  padding-top: 0;
  padding-bottom: 0;
  padding-left: 4px;
  padding-right: 4px;
}

#rczwvfjjqe .gt_column_spanner_outer:first-child {
  padding-left: 0;
}

#rczwvfjjqe .gt_column_spanner_outer:last-child {
  padding-right: 0;
}

#rczwvfjjqe .gt_column_spanner {
  border-bottom-style: none;
  border-bottom-width: 1px;
  border-bottom-color: #334422;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 5px;
  overflow-x: hidden;
  display: inline-block;
  width: 100%;
}

#rczwvfjjqe .gt_spanner_row {
  border-bottom-style: hidden;
}

#rczwvfjjqe .gt_group_heading {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  text-align: left;
}

#rczwvfjjqe .gt_empty_group_heading {
  padding: 0.5px;
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: middle;
}

#rczwvfjjqe .gt_from_md > :first-child {
  margin-top: 0;
}

#rczwvfjjqe .gt_from_md > :last-child {
  margin-bottom: 0;
}

#rczwvfjjqe .gt_row {
  padding-top: 7px;
  padding-bottom: 7px;
  padding-left: 5px;
  padding-right: 5px;
  margin: 10px;
  border-top-style: solid;
  border-top-width: 1px;
  border-top-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  overflow-x: hidden;
}

#rczwvfjjqe .gt_stub {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 5px;
  padding-right: 5px;
}

#rczwvfjjqe .gt_stub_row_group {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 5px;
  padding-right: 5px;
  vertical-align: top;
}

#rczwvfjjqe .gt_row_group_first td {
  border-top-width: 2px;
}

#rczwvfjjqe .gt_row_group_first th {
  border-top-width: 2px;
}

#rczwvfjjqe .gt_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#rczwvfjjqe .gt_first_summary_row {
  border-top-style: solid;
  border-top-color: #D3D3D3;
}

#rczwvfjjqe .gt_first_summary_row.thick {
  border-top-width: 2px;
}

#rczwvfjjqe .gt_last_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#rczwvfjjqe .gt_grand_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#rczwvfjjqe .gt_first_grand_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: double;
  border-top-width: 6px;
  border-top-color: #D3D3D3;
}

#rczwvfjjqe .gt_last_grand_summary_row_top {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-bottom-style: double;
  border-bottom-width: 6px;
  border-bottom-color: #D3D3D3;
}

#rczwvfjjqe .gt_striped {
  background-color: rgba(128, 128, 128, 0.05);
}

#rczwvfjjqe .gt_table_body {
  border-top-style: none;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #FFFFFF;
}

#rczwvfjjqe .gt_footnotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#rczwvfjjqe .gt_footnote {
  margin: 0px;
  font-size: 90%;
  padding-top: 4px;
  padding-bottom: 4px;
  padding-left: 5px;
  padding-right: 5px;
}

#rczwvfjjqe .gt_sourcenotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#rczwvfjjqe .gt_sourcenote {
  font-size: 90%;
  padding-top: 4px;
  padding-bottom: 4px;
  padding-left: 5px;
  padding-right: 5px;
}

#rczwvfjjqe .gt_left {
  text-align: left;
}

#rczwvfjjqe .gt_center {
  text-align: center;
}

#rczwvfjjqe .gt_right {
  text-align: right;
  font-variant-numeric: tabular-nums;
}

#rczwvfjjqe .gt_font_normal {
  font-weight: normal;
}

#rczwvfjjqe .gt_font_bold {
  font-weight: bold;
}

#rczwvfjjqe .gt_font_italic {
  font-style: italic;
}

#rczwvfjjqe .gt_super {
  font-size: 65%;
}

#rczwvfjjqe .gt_footnote_marks {
  font-size: 75%;
  vertical-align: 0.4em;
  position: initial;
}

#rczwvfjjqe .gt_asterisk {
  font-size: 100%;
  vertical-align: 0;
}

#rczwvfjjqe .gt_indent_1 {
  text-indent: 5px;
}

#rczwvfjjqe .gt_indent_2 {
  text-indent: 10px;
}

#rczwvfjjqe .gt_indent_3 {
  text-indent: 15px;
}

#rczwvfjjqe .gt_indent_4 {
  text-indent: 20px;
}

#rczwvfjjqe .gt_indent_5 {
  text-indent: 25px;
}
</style>

<table class="gt_table caption-top table table-sm table-striped small" data-quarto-postprocess="true" data-quarto-disable-processing="false" data-quarto-bootstrap="false">
<thead>
<tr class="gt_heading header">
<th colspan="6" class="gt_heading gt_title gt_font_normal gt_bottom_border" style="text-align: center; font-family: 'Libre Franklin'; font-weight: 800;">CTCAE Grades</th>
</tr>
<tr class="gt_col_headings even">
<th id="CTCAE Term" class="gt_col_heading gt_columns_bottom_border gt_left" data-quarto-table-cell-role="th" style="text-align: center; color: #A9A9A9; font-family: 'Source Sans Pro'; text-transform: uppercase;" scope="col">CTCAE Term</th>
<th id="Grade 1" class="gt_col_heading gt_columns_bottom_border gt_left" data-quarto-table-cell-role="th" style="text-align: center; color: #A9A9A9; font-family: 'Source Sans Pro'; text-transform: uppercase;" scope="col">Grade 1</th>
<th id="Grade 2" class="gt_col_heading gt_columns_bottom_border gt_left" data-quarto-table-cell-role="th" style="text-align: center; color: #A9A9A9; font-family: 'Source Sans Pro'; text-transform: uppercase;" scope="col">Grade 2</th>
<th id="Grade 3" class="gt_col_heading gt_columns_bottom_border gt_left" data-quarto-table-cell-role="th" style="text-align: center; color: #A9A9A9; font-family: 'Source Sans Pro'; text-transform: uppercase;" scope="col">Grade 3</th>
<th id="Grade 4" class="gt_col_heading gt_columns_bottom_border gt_left" data-quarto-table-cell-role="th" style="text-align: center; color: #A9A9A9; font-family: 'Source Sans Pro'; text-transform: uppercase;" scope="col">Grade 4</th>
<th id="Grade 5" class="gt_col_heading gt_columns_bottom_border gt_left" data-quarto-table-cell-role="th" style="text-align: center; color: #A9A9A9; font-family: 'Source Sans Pro'; text-transform: uppercase;" scope="col">Grade 5</th>
</tr>
</thead>
<tbody class="gt_table_body">
<tr class="gt_group_heading_row odd">
<td colspan="6" id="Gastrointestinal" class="gt_group_heading" data-quarto-table-cell-role="th" style="text-align: center; color: #FF0000; font-weight: bold;" scope="colgroup">Gastrointestinal</td>
</tr>
<tr class="gt_row_group_first even">
<td class="gt_row gt_left" headers="Gastrointestinal  CTCAE Term" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Diarrhea</td>
<td class="gt_row gt_left" headers="Gastrointestinal  Grade 1" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Increase of &lt;4 stools per day over baseline; mild increase in ostomy output compared to baseline</td>
<td class="gt_row gt_left" headers="Gastrointestinal  Grade 2" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Increase of 4 - 6 stools per day over baseline; moderate increase in ostomy output compared to baseline; limiting instrumental ADL</td>
<td class="gt_row gt_left" headers="Gastrointestinal  Grade 3" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Increase of &gt;=7 stools per day over baseline; hospitalization indicated; severe increase in ostomy output compared to baseline; limiting self care ADL</td>
<td class="gt_row gt_left" headers="Gastrointestinal  Grade 4" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Life-threatening consequences; urgent intervention indicated</td>
<td class="gt_row gt_left" headers="Gastrointestinal  Grade 5" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Death</td>
</tr>
<tr class="odd">
<td class="gt_row gt_left gt_striped" headers="Gastrointestinal  CTCAE Term" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Lower gastrointestinal hemorrhage</td>
<td class="gt_row gt_left gt_striped" headers="Gastrointestinal  Grade 1" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Mild symptoms; intervention not indicated</td>
<td class="gt_row gt_left gt_striped" headers="Gastrointestinal  Grade 2" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Moderate symptoms; intervention indicated</td>
<td class="gt_row gt_left gt_striped" headers="Gastrointestinal  Grade 3" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Transfusion indicated; invasive intervention indicated; hospitalization</td>
<td class="gt_row gt_left gt_striped" headers="Gastrointestinal  Grade 4" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Life-threatening consequences; urgent intervention indicated</td>
<td class="gt_row gt_left gt_striped" headers="Gastrointestinal  Grade 5" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Death</td>
</tr>
<tr class="even">
<td class="gt_row gt_left" headers="Gastrointestinal  CTCAE Term" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Fecal incontinence</td>
<td class="gt_row gt_left" headers="Gastrointestinal  Grade 1" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Occasional use of pads required</td>
<td class="gt_row gt_left" headers="Gastrointestinal  Grade 2" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Daily use of pads required</td>
<td class="gt_row gt_left" headers="Gastrointestinal  Grade 3" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Severe symptoms; elective operative intervention indicated</td>
<td class="gt_row gt_left" headers="Gastrointestinal  Grade 4" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
<td class="gt_row gt_left" headers="Gastrointestinal  Grade 5" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
</tr>
<tr class="odd">
<td class="gt_row gt_left gt_striped" headers="Gastrointestinal  CTCAE Term" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Gastrointestinal pain</td>
<td class="gt_row gt_left gt_striped" headers="Gastrointestinal  Grade 1" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Mild pain</td>
<td class="gt_row gt_left gt_striped" headers="Gastrointestinal  Grade 2" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Moderate pain; limiting instrumental ADL</td>
<td class="gt_row gt_left gt_striped" headers="Gastrointestinal  Grade 3" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Severe pain; limiting self care ADL</td>
<td class="gt_row gt_left gt_striped" headers="Gastrointestinal  Grade 4" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
<td class="gt_row gt_left gt_striped" headers="Gastrointestinal  Grade 5" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
</tr>
<tr class="even">
<td class="gt_row gt_left" headers="Gastrointestinal  CTCAE Term" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Proctitis</td>
<td class="gt_row gt_left" headers="Gastrointestinal  Grade 1" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Rectal discomfort, intervention not indicated</td>
<td class="gt_row gt_left" headers="Gastrointestinal  Grade 2" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Symptomatic (e.g., rectal discomfort, passing blood or mucus); medical intervention indicated; limiting instrumental ADL</td>
<td class="gt_row gt_left" headers="Gastrointestinal  Grade 3" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Severe symptoms; fecal urgency or stool incontinence; limiting self care ADL</td>
<td class="gt_row gt_left" headers="Gastrointestinal  Grade 4" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Life-threatening consequences; urgent intervention indicated</td>
<td class="gt_row gt_left" headers="Gastrointestinal  Grade 5" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
</tr>
<tr class="gt_group_heading_row odd">
<td colspan="6" id="Chemotherapy-related" class="gt_group_heading" data-quarto-table-cell-role="th" style="text-align: center; color: #FF0000; font-weight: bold;" scope="colgroup">Chemotherapy-related</td>
</tr>
<tr class="gt_row_group_first even">
<td class="gt_row gt_left gt_striped" headers="Chemotherapy-related  CTCAE Term" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Nausea</td>
<td class="gt_row gt_left gt_striped" headers="Chemotherapy-related  Grade 1" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Loss of appetite without alteration in eating habits</td>
<td class="gt_row gt_left gt_striped" headers="Chemotherapy-related  Grade 2" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Oral intake decreased without significant weight loss, dehydration or malnutrition</td>
<td class="gt_row gt_left gt_striped" headers="Chemotherapy-related  Grade 3" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated</td>
<td class="gt_row gt_left gt_striped" headers="Chemotherapy-related  Grade 4" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
<td class="gt_row gt_left gt_striped" headers="Chemotherapy-related  Grade 5" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
</tr>
<tr class="odd">
<td class="gt_row gt_left" headers="Chemotherapy-related  CTCAE Term" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Vomiting</td>
<td class="gt_row gt_left" headers="Chemotherapy-related  Grade 1" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Intervention not indicated</td>
<td class="gt_row gt_left" headers="Chemotherapy-related  Grade 2" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Outpatient IV hydration; medical intervention indicated</td>
<td class="gt_row gt_left" headers="Chemotherapy-related  Grade 3" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Tube feeding, TPN, or hospitalization indicated</td>
<td class="gt_row gt_left" headers="Chemotherapy-related  Grade 4" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
<td class="gt_row gt_left" headers="Chemotherapy-related  Grade 5" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
</tr>
<tr class="even">
<td class="gt_row gt_left gt_striped" headers="Chemotherapy-related  CTCAE Term" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Anemia</td>
<td class="gt_row gt_left gt_striped" headers="Chemotherapy-related  Grade 1" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Hemoglobin (Hgb) &lt;LLN - 10.0 g/dL; &lt;LLN - 6.2 mmol/L; &lt;LLN - 100 g/L</td>
<td class="gt_row gt_left gt_striped" headers="Chemotherapy-related  Grade 2" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Hgb &lt;10.0 - 8.0 g/dL; &lt;6.2 - 4.9 mmol/L; &lt;100 - 80g/L</td>
<td class="gt_row gt_left gt_striped" headers="Chemotherapy-related  Grade 3" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Hgb &lt;8.0 g/dL; &lt;4.9 mmol/L; &lt;80 g/L; transfusion indicated</td>
<td class="gt_row gt_left gt_striped" headers="Chemotherapy-related  Grade 4" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Life-threatening consequences; urgent intervention indicated</td>
<td class="gt_row gt_left gt_striped" headers="Chemotherapy-related  Grade 5" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
</tr>
<tr class="odd">
<td class="gt_row gt_left" headers="Chemotherapy-related  CTCAE Term" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Platelet count decreased</td>
<td class="gt_row gt_left" headers="Chemotherapy-related  Grade 1" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">&lt;LLN - 75,000/mm3; &lt;LLN - 75.0 x 10e9 /L</td>
<td class="gt_row gt_left" headers="Chemotherapy-related  Grade 2" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">&lt;75,000 - 50,000/mm3; &lt;75.0 - 50.0 x 10e9 /L</td>
<td class="gt_row gt_left" headers="Chemotherapy-related  Grade 3" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">&lt;50,000 - 25,000/mm3; &lt;50.0 - 25.0 x 10e9 /L</td>
<td class="gt_row gt_left" headers="Chemotherapy-related  Grade 4" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">&lt;25,000/mm3; &lt;25.0 x 10e9 /L</td>
<td class="gt_row gt_left" headers="Chemotherapy-related  Grade 5" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
</tr>
<tr class="even">
<td class="gt_row gt_left gt_striped" headers="Chemotherapy-related  CTCAE Term" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">White blood cell decreased</td>
<td class="gt_row gt_left gt_striped" headers="Chemotherapy-related  Grade 1" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">&lt;LLN - 3000/mm3; &lt;LLN - 3.0 x 10e9 /L</td>
<td class="gt_row gt_left gt_striped" headers="Chemotherapy-related  Grade 2" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">&lt;3000 - 2000/mm3; &lt;3.0 - 2.0 x 10e9 /L</td>
<td class="gt_row gt_left gt_striped" headers="Chemotherapy-related  Grade 3" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">&lt;2000 - 1000/mm3; &lt;2.0 - 1.0 x 10e9 /L</td>
<td class="gt_row gt_left gt_striped" headers="Chemotherapy-related  Grade 4" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">&lt;1000/mm3; &lt;1.0 x 10e9 /L</td>
<td class="gt_row gt_left gt_striped" headers="Chemotherapy-related  Grade 5" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
</tr>
<tr class="gt_group_heading_row odd">
<td colspan="6" id="Skin" class="gt_group_heading" data-quarto-table-cell-role="th" style="text-align: center; color: #FF0000; font-weight: bold;" scope="colgroup">Skin</td>
</tr>
<tr class="gt_row_group_first even">
<td class="gt_row gt_left" headers="Skin  CTCAE Term" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Dermatitis</td>
<td class="gt_row gt_left" headers="Skin  Grade 1" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Faint erythema or dry desquamation</td>
<td class="gt_row gt_left" headers="Skin  Grade 2" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Moderate to brisk erythema; patchy moist desquamation, mostly confined to skin folds and creases; moderate edema</td>
<td class="gt_row gt_left" headers="Skin  Grade 3" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Moist desquamation in areas other than skin folds and creases; bleeding induced by minor trauma or abrasion</td>
<td class="gt_row gt_left" headers="Skin  Grade 4" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Life-threatening consequences; skin necrosis or ulceration of full thickness dermis; spontaneous bleeding from involved site; skin graft indicated</td>
<td class="gt_row gt_left" headers="Skin  Grade 5" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Death</td>
</tr>
<tr class="gt_group_heading_row odd">
<td colspan="6" id="Urinary-Symptoms" class="gt_group_heading" data-quarto-table-cell-role="th" style="text-align: center; color: #FF0000; font-weight: bold;" scope="colgroup">Urinary-Symptoms</td>
</tr>
<tr class="gt_row_group_first even">
<td class="gt_row gt_left gt_striped" headers="Urinary-Symptoms  CTCAE Term" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Dysuria</td>
<td class="gt_row gt_left gt_striped" headers="Urinary-Symptoms  Grade 1" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Present</td>
<td class="gt_row gt_left gt_striped" headers="Urinary-Symptoms  Grade 2" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
<td class="gt_row gt_left gt_striped" headers="Urinary-Symptoms  Grade 3" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
<td class="gt_row gt_left gt_striped" headers="Urinary-Symptoms  Grade 4" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
<td class="gt_row gt_left gt_striped" headers="Urinary-Symptoms  Grade 5" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
</tr>
<tr class="odd">
<td class="gt_row gt_left" headers="Urinary-Symptoms  CTCAE Term" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Hematuria</td>
<td class="gt_row gt_left" headers="Urinary-Symptoms  Grade 1" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Asymptomatic; clinical or diagnostic observations only; intervention not indicated</td>
<td class="gt_row gt_left" headers="Urinary-Symptoms  Grade 2" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Symptomatic; urinary catheter or bladder irrigation indicated; limiting instrumental ADL</td>
<td class="gt_row gt_left" headers="Urinary-Symptoms  Grade 3" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Gross hematuria; transfusion, IV medications, or hospitalization indicated; elective invasive intervention indicated; limiting self care ADL</td>
<td class="gt_row gt_left" headers="Urinary-Symptoms  Grade 4" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Life-threatening consequences; urgent invasive intervention indicated</td>
<td class="gt_row gt_left" headers="Urinary-Symptoms  Grade 5" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Death</td>
</tr>
<tr class="even">
<td class="gt_row gt_left gt_striped" headers="Urinary-Symptoms  CTCAE Term" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Urinary frequency</td>
<td class="gt_row gt_left gt_striped" headers="Urinary-Symptoms  Grade 1" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Present</td>
<td class="gt_row gt_left gt_striped" headers="Urinary-Symptoms  Grade 2" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Limiting instrumental ADL; medical management indicated</td>
<td class="gt_row gt_left gt_striped" headers="Urinary-Symptoms  Grade 3" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
<td class="gt_row gt_left gt_striped" headers="Urinary-Symptoms  Grade 4" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
<td class="gt_row gt_left gt_striped" headers="Urinary-Symptoms  Grade 5" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
</tr>
<tr class="odd">
<td class="gt_row gt_left" headers="Urinary-Symptoms  CTCAE Term" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Urinary incontinence</td>
<td class="gt_row gt_left" headers="Urinary-Symptoms  Grade 1" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Occasional (e.g., with coughing, sneezing, etc.), pads not indicated</td>
<td class="gt_row gt_left" headers="Urinary-Symptoms  Grade 2" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Spontaneous; pads indicated; limiting instrumental ADL</td>
<td class="gt_row gt_left" headers="Urinary-Symptoms  Grade 3" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Intervention indicated (e.g., clamp, collagen injections); operative intervention indicated; limiting self care ADL</td>
<td class="gt_row gt_left" headers="Urinary-Symptoms  Grade 4" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
<td class="gt_row gt_left" headers="Urinary-Symptoms  Grade 5" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
</tr>
<tr class="even">
<td class="gt_row gt_left gt_striped" headers="Urinary-Symptoms  CTCAE Term" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Urinary tract pain</td>
<td class="gt_row gt_left gt_striped" headers="Urinary-Symptoms  Grade 1" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Mild pain</td>
<td class="gt_row gt_left gt_striped" headers="Urinary-Symptoms  Grade 2" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Moderate pain; limiting instrumental ADL</td>
<td class="gt_row gt_left gt_striped" headers="Urinary-Symptoms  Grade 3" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Severe pain; limiting self care ADL</td>
<td class="gt_row gt_left gt_striped" headers="Urinary-Symptoms  Grade 4" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
<td class="gt_row gt_left gt_striped" headers="Urinary-Symptoms  Grade 5" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
</tr>
<tr class="odd">
<td class="gt_row gt_left" headers="Urinary-Symptoms  CTCAE Term" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Urinary urgency</td>
<td class="gt_row gt_left" headers="Urinary-Symptoms  Grade 1" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Present</td>
<td class="gt_row gt_left" headers="Urinary-Symptoms  Grade 2" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Limiting instrumental ADL; medical management indicated</td>
<td class="gt_row gt_left" headers="Urinary-Symptoms  Grade 3" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
<td class="gt_row gt_left" headers="Urinary-Symptoms  Grade 4" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
<td class="gt_row gt_left" headers="Urinary-Symptoms  Grade 5" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
</tr>
<tr class="gt_group_heading_row even">
<td colspan="6" id="Others" class="gt_group_heading" data-quarto-table-cell-role="th" style="text-align: center; color: #FF0000; font-weight: bold;" scope="colgroup">Others</td>
</tr>
<tr class="gt_row_group_first odd">
<td class="gt_row gt_left gt_striped" headers="Others  CTCAE Term" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Erectile dysfunction</td>
<td class="gt_row gt_left gt_striped" headers="Others  Grade 1" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Decrease in erectile function (frequency or rigidity of erections) but intervention not indicated (e.g., medication or use of mechanical device, penile pump)</td>
<td class="gt_row gt_left gt_striped" headers="Others  Grade 2" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Decrease in erectile function (frequency/rigidity of erections), erectile intervention indicated, (e.g., medication or mechanical devices such as penile pump)</td>
<td class="gt_row gt_left gt_striped" headers="Others  Grade 3" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Decrease in erectile function (frequency/rigidity of erections) but erectile intervention not helpful (e.g., medication or mechanical devices such as penile pump); placement of a permanent penile prosthesis indicated (not previously present)</td>
<td class="gt_row gt_left gt_striped" headers="Others  Grade 4" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
<td class="gt_row gt_left gt_striped" headers="Others  Grade 5" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
</tr>
<tr class="even">
<td class="gt_row gt_left" headers="Others  CTCAE Term" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Fatigue</td>
<td class="gt_row gt_left" headers="Others  Grade 1" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Fatigue relieved by rest</td>
<td class="gt_row gt_left" headers="Others  Grade 2" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Fatigue not relieved by rest; limiting instrumental ADL</td>
<td class="gt_row gt_left" headers="Others  Grade 3" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Fatigue not relieved by rest, limiting self care ADL</td>
<td class="gt_row gt_left" headers="Others  Grade 4" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
<td class="gt_row gt_left" headers="Others  Grade 5" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
</tr>
</tbody>
</table>

</div>
</div>
</div>
</section>
<section id="bei-gleichzeitige-systemische-therapie" class="level2">
<h2 class="anchored" data-anchor-id="bei-gleichzeitige-systemische-therapie">Bei gleichzeitige systemische Therapie</h2>
<p>Folgendes <strong>muss</strong> dokumentiert werden:</p>
<ul>
<li>Capecitabin-Dosierung
<ul>
<li>Bzw. Protokolle für die kontinuierliche 5-FU-Infusion</li>
</ul></li>
<li>Die Laborüberwachung</li>
</ul>
</section>
</section>
<section id="nachsorge" class="level1">
<h1>Nachsorge</h1>
<p>Leider wird den Leitlinien nicht immer gefolgt. So zeigte sich, dass bei Menschen jenseits des 65.Lebensjahres nur in 73,6% der Fälle die empfohlenen Koloskopien und lediglich bei 46,7% eine Bestimmung des CEA erfolgte, während nicht empfohlene Maßnahmen wie CT und PET-CT bei 48% bzw. 7% durchgeführt wurden.<span class="citation" data-cites="DeutscheKrebsgesellschaftEtAl2019"><sup><a href="#ref-DeutscheKrebsgesellschaftEtAl2019" role="doc-biblioref">1</a></sup></span></p>
<section id="bewertung-des-ansprechens-auf-die-behandlung" class="level2">
<h2 class="anchored" data-anchor-id="bewertung-des-ansprechens-auf-die-behandlung">Bewertung des Ansprechens auf die Behandlung</h2>
<p>Durch die neoadjuvante Radiochemotherapie und entsprechende Remission kann u. U. trotz primär nicht für möglich gehaltenen Sphinktererhaltes eine Schließmuskel erhaltende Rektumresektion möglich werden. Deshalb sollte diesbezüglich frühestens 6 Wochen nach Abschluss der Radiochemotherapie eine Reevaluation stattfinden.<span class="citation" data-cites="DeutscheKrebsgesellschaftEtAl2019"><sup><a href="#ref-DeutscheKrebsgesellschaftEtAl2019" role="doc-biblioref">1</a></sup></span></p>
</section>
<section id="cea-bestimmung-in-der-nachsorge" class="level2">
<h2 class="anchored" data-anchor-id="cea-bestimmung-in-der-nachsorge">CEA Bestimmung in der Nachsorge</h2>
<p>Die Bestimmung des karzinoembryonalen Antigens (CEA) wird alle 6 Monate für mindestens 2 Jahre empfohlen. Ein erhöhter CEA-Wert erfordert eine weitere Diagnostik.<span class="citation" data-cites="DeutscheKrebsgesellschaftEtAl2019"><sup><a href="#ref-DeutscheKrebsgesellschaftEtAl2019" role="doc-biblioref">1</a></sup></span></p>
</section>
</section>
<section id="wichtige-studien" class="level1">
<h1>Wichtige Studien</h1>
<div class="cell">
<div class="cell-output-display">
<div id="qrybuloucx" style="padding-left:0px;padding-right:0px;padding-top:10px;padding-bottom:10px;overflow-x:auto;overflow-y:auto;width:auto;height:auto;">
<style>@import url("https://fonts.googleapis.com/css2?family=Source+Sans+Pro:ital,wght@0,100;0,200;0,300;0,400;0,500;0,600;0,700;0,800;0,900;1,100;1,200;1,300;1,400;1,500;1,600;1,700;1,800;1,900&display=swap");
@import url("https://fonts.googleapis.com/css2?family=Libre+Franklin:ital,wght@0,100;0,200;0,300;0,400;0,500;0,600;0,700;0,800;0,900;1,100;1,200;1,300;1,400;1,500;1,600;1,700;1,800;1,900&display=swap");
@import url("https://fonts.googleapis.com/css2?family=Source+Sans+Pro:ital,wght@0,100;0,200;0,300;0,400;0,500;0,600;0,700;0,800;0,900;1,100;1,200;1,300;1,400;1,500;1,600;1,700;1,800;1,900&display=swap");
#qrybuloucx table {
  font-family: system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji';
  -webkit-font-smoothing: antialiased;
  -moz-osx-font-smoothing: grayscale;
}

#qrybuloucx thead, #qrybuloucx tbody, #qrybuloucx tfoot, #qrybuloucx tr, #qrybuloucx td, #qrybuloucx th {
  border-style: none;
}

#qrybuloucx p {
  margin: 0;
  padding: 0;
}

#qrybuloucx .gt_table {
  display: table;
  border-collapse: collapse;
  line-height: normal;
  margin-left: auto;
  margin-right: auto;
  color: #333333;
  font-size: 16px;
  font-weight: normal;
  font-style: normal;
  background-color: #FFFFFF;
  width: auto;
  border-top-style: none;
  border-top-width: 2px;
  border-top-color: #A8A8A8;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #A8A8A8;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
}

#qrybuloucx .gt_caption {
  padding-top: 4px;
  padding-bottom: 4px;
}

#qrybuloucx .gt_title {
  color: #333333;
  font-size: 125%;
  font-weight: initial;
  padding-top: 4px;
  padding-bottom: 4px;
  padding-left: 5px;
  padding-right: 5px;
  border-bottom-color: #FFFFFF;
  border-bottom-width: 0;
}

#qrybuloucx .gt_subtitle {
  color: #333333;
  font-size: 85%;
  font-weight: initial;
  padding-top: 3px;
  padding-bottom: 5px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-color: #FFFFFF;
  border-top-width: 0;
}

#qrybuloucx .gt_heading {
  background-color: #FFFFFF;
  text-align: left;
  border-bottom-color: #FFFFFF;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#qrybuloucx .gt_bottom_border {
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#qrybuloucx .gt_col_headings {
  border-top-style: none;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: none;
  border-bottom-width: 1px;
  border-bottom-color: #334422;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#qrybuloucx .gt_col_heading {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 12px;
  font-weight: normal;
  text-transform: inherit;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 6px;
  padding-left: 5px;
  padding-right: 5px;
  overflow-x: hidden;
}

#qrybuloucx .gt_column_spanner_outer {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 12px;
  font-weight: normal;
  text-transform: inherit;
  padding-top: 0;
  padding-bottom: 0;
  padding-left: 4px;
  padding-right: 4px;
}

#qrybuloucx .gt_column_spanner_outer:first-child {
  padding-left: 0;
}

#qrybuloucx .gt_column_spanner_outer:last-child {
  padding-right: 0;
}

#qrybuloucx .gt_column_spanner {
  border-bottom-style: none;
  border-bottom-width: 1px;
  border-bottom-color: #334422;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 5px;
  overflow-x: hidden;
  display: inline-block;
  width: 100%;
}

#qrybuloucx .gt_spanner_row {
  border-bottom-style: hidden;
}

#qrybuloucx .gt_group_heading {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  text-align: left;
}

#qrybuloucx .gt_empty_group_heading {
  padding: 0.5px;
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: middle;
}

#qrybuloucx .gt_from_md > :first-child {
  margin-top: 0;
}

#qrybuloucx .gt_from_md > :last-child {
  margin-bottom: 0;
}

#qrybuloucx .gt_row {
  padding-top: 7px;
  padding-bottom: 7px;
  padding-left: 5px;
  padding-right: 5px;
  margin: 10px;
  border-top-style: solid;
  border-top-width: 1px;
  border-top-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  overflow-x: hidden;
}

#qrybuloucx .gt_stub {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 5px;
  padding-right: 5px;
}

#qrybuloucx .gt_stub_row_group {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 5px;
  padding-right: 5px;
  vertical-align: top;
}

#qrybuloucx .gt_row_group_first td {
  border-top-width: 2px;
}

#qrybuloucx .gt_row_group_first th {
  border-top-width: 2px;
}

#qrybuloucx .gt_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#qrybuloucx .gt_first_summary_row {
  border-top-style: solid;
  border-top-color: #D3D3D3;
}

#qrybuloucx .gt_first_summary_row.thick {
  border-top-width: 2px;
}

#qrybuloucx .gt_last_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#qrybuloucx .gt_grand_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#qrybuloucx .gt_first_grand_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: double;
  border-top-width: 6px;
  border-top-color: #D3D3D3;
}

#qrybuloucx .gt_last_grand_summary_row_top {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-bottom-style: double;
  border-bottom-width: 6px;
  border-bottom-color: #D3D3D3;
}

#qrybuloucx .gt_striped {
  background-color: rgba(128, 128, 128, 0.05);
}

#qrybuloucx .gt_table_body {
  border-top-style: none;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #FFFFFF;
}

#qrybuloucx .gt_footnotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#qrybuloucx .gt_footnote {
  margin: 0px;
  font-size: 90%;
  padding-top: 4px;
  padding-bottom: 4px;
  padding-left: 5px;
  padding-right: 5px;
}

#qrybuloucx .gt_sourcenotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#qrybuloucx .gt_sourcenote {
  font-size: 90%;
  padding-top: 4px;
  padding-bottom: 4px;
  padding-left: 5px;
  padding-right: 5px;
}

#qrybuloucx .gt_left {
  text-align: left;
}

#qrybuloucx .gt_center {
  text-align: center;
}

#qrybuloucx .gt_right {
  text-align: right;
  font-variant-numeric: tabular-nums;
}

#qrybuloucx .gt_font_normal {
  font-weight: normal;
}

#qrybuloucx .gt_font_bold {
  font-weight: bold;
}

#qrybuloucx .gt_font_italic {
  font-style: italic;
}

#qrybuloucx .gt_super {
  font-size: 65%;
}

#qrybuloucx .gt_footnote_marks {
  font-size: 75%;
  vertical-align: 0.4em;
  position: initial;
}

#qrybuloucx .gt_asterisk {
  font-size: 100%;
  vertical-align: 0;
}

#qrybuloucx .gt_indent_1 {
  text-indent: 5px;
}

#qrybuloucx .gt_indent_2 {
  text-indent: 10px;
}

#qrybuloucx .gt_indent_3 {
  text-indent: 15px;
}

#qrybuloucx .gt_indent_4 {
  text-indent: 20px;
}

#qrybuloucx .gt_indent_5 {
  text-indent: 25px;
}
</style>

<table class="gt_table caption-top table table-sm table-striped small" data-quarto-postprocess="true" data-quarto-disable-processing="false" data-quarto-bootstrap="false">
<colgroup>
<col style="width: 10%">
<col style="width: 10%">
<col style="width: 10%">
<col style="width: 10%">
<col style="width: 10%">
<col style="width: 10%">
<col style="width: 10%">
<col style="width: 10%">
<col style="width: 10%">
<col style="width: 10%">
</colgroup>
<thead>
<tr class="gt_heading header">
<th colspan="10" class="gt_heading gt_title gt_font_normal" style="text-align: center; font-family: 'Libre Franklin'; font-weight: 800;"><strong>Clinical Trials in Rectal Cancer Treatment</strong></th>
</tr>
<tr class="gt_heading even">
<th colspan="10" class="gt_heading gt_subtitle gt_font_normal gt_bottom_border" style="text-align: center;"><em>Grouped by Treatment Category</em></th>
</tr>
<tr class="gt_col_headings header">
<th id="Study" class="gt_col_heading gt_columns_bottom_border gt_left" data-quarto-table-cell-role="th" style="text-align: center; color: #A9A9A9; font-family: 'Source Sans Pro'; text-transform: uppercase;" scope="col">Study</th>
<th id="Year" class="gt_col_heading gt_columns_bottom_border gt_right" data-quarto-table-cell-role="th" style="text-align: center; color: #A9A9A9; font-family: 'Source Sans Pro'; text-transform: uppercase;" scope="col">Year</th>
<th id="Tumor characteristics" class="gt_col_heading gt_columns_bottom_border gt_left" data-quarto-table-cell-role="th" style="text-align: center; color: #A9A9A9; font-family: 'Source Sans Pro'; text-transform: uppercase;" scope="col">Tumor characteristics</th>
<th id="Tumor location" class="gt_col_heading gt_columns_bottom_border gt_left" data-quarto-table-cell-role="th" style="text-align: center; color: #A9A9A9; font-family: 'Source Sans Pro'; text-transform: uppercase;" scope="col">Tumor location</th>
<th id="Age" class="gt_col_heading gt_columns_bottom_border gt_left" data-quarto-table-cell-role="th" style="text-align: center; color: #A9A9A9; font-family: 'Source Sans Pro'; text-transform: uppercase;" scope="col">Age</th>
<th id="Experimental Arms" class="gt_col_heading gt_columns_bottom_border gt_left" data-quarto-table-cell-role="th" style="text-align: center; color: #A9A9A9; font-family: 'Source Sans Pro'; text-transform: uppercase;" scope="col">Experimental Arms</th>
<th id="standard of care" class="gt_col_heading gt_columns_bottom_border gt_left" data-quarto-table-cell-role="th" style="text-align: center; color: #A9A9A9; font-family: 'Source Sans Pro'; text-transform: uppercase;" scope="col">standard of care</th>
<th id="Radiation Type" class="gt_col_heading gt_columns_bottom_border gt_left" data-quarto-table-cell-role="th" style="text-align: center; color: #A9A9A9; font-family: 'Source Sans Pro'; text-transform: uppercase;" scope="col">Radiation Type</th>
<th id="Primary Outcome" class="gt_col_heading gt_columns_bottom_border gt_left" data-quarto-table-cell-role="th" style="text-align: center; color: #A9A9A9; font-family: 'Source Sans Pro'; text-transform: uppercase;" scope="col">Primary Outcome</th>
<th id="Key Findings" class="gt_col_heading gt_columns_bottom_border gt_left" data-quarto-table-cell-role="th" style="text-align: center; color: #A9A9A9; font-family: 'Source Sans Pro'; text-transform: uppercase;" scope="col">Key Findings</th>
</tr>
</thead>
<tbody class="gt_table_body">
<tr class="gt_group_heading_row odd">
<td colspan="10" id="Immunotherapy for dMMR" class="gt_group_heading" data-quarto-table-cell-role="th" style="text-align: center; color: #FF0000; font-weight: bold;" scope="colgroup">Immunotherapy for dMMR</td>
</tr>
<tr class="gt_row_group_first even">
<td class="gt_row gt_left" headers="Immunotherapy for dMMR  Study" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;"><p>Cercek et al.</p></td>
<td class="gt_row gt_right" headers="Immunotherapy for dMMR  Year" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">2022</td>
<td class="gt_row gt_left" headers="Immunotherapy for dMMR  Tumor characteristics" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">dMMR stage II/III rectal cancer</td>
<td class="gt_row gt_left" headers="Immunotherapy for dMMR  Tumor location" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
<td class="gt_row gt_left" headers="Immunotherapy for dMMR  Age" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
<td class="gt_row gt_left" headers="Immunotherapy for dMMR  Experimental Arms" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Dostarlimab 9× every 3 wks for 6 mo, if no cCR → CRT 50,4Gy/28f</td>
<td class="gt_row gt_left" headers="Immunotherapy for dMMR  standard of care" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
<td class="gt_row gt_left" headers="Immunotherapy for dMMR  Radiation Type" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">None</td>
<td class="gt_row gt_left" headers="Immunotherapy for dMMR  Primary Outcome" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">cCR</td>
<td class="gt_row gt_left" headers="Immunotherapy for dMMR  Key Findings" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">100% (12/12) had cCR, no grade ≥3 adverse events</td>
</tr>
<tr class="gt_group_heading_row odd">
<td colspan="10" id="Neoadjuvant vs Adjuvant CRT" class="gt_group_heading" data-quarto-table-cell-role="th" style="text-align: center; color: #FF0000; font-weight: bold;" scope="colgroup">Neoadjuvant vs Adjuvant CRT</td>
</tr>
<tr class="gt_row_group_first even">
<td class="gt_row gt_left gt_striped" headers="Neoadjuvant vs Adjuvant CRT  Study" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;"><p>CAO/ARO/AIO-94</p></td>
<td class="gt_row gt_right gt_striped" headers="Neoadjuvant vs Adjuvant CRT  Year" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">2004</td>
<td class="gt_row gt_left gt_striped" headers="Neoadjuvant vs Adjuvant CRT  Tumor characteristics" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">T3–T4 or N+</td>
<td class="gt_row gt_left gt_striped" headers="Neoadjuvant vs Adjuvant CRT  Tumor location" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">≤ 16 cm from anal verge</td>
<td class="gt_row gt_left gt_striped" headers="Neoadjuvant vs Adjuvant CRT  Age" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">18–75</td>
<td class="gt_row gt_left gt_striped" headers="Neoadjuvant vs Adjuvant CRT  Experimental Arms" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">CRT 50,4 Gy/28f → TME → 4× FU 500 mg/m2</td>
<td class="gt_row gt_left gt_striped" headers="Neoadjuvant vs Adjuvant CRT  standard of care" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">TME → CRT 50,4 Gy/28f + 5,4 Gy Boost to Tumor bed → 4× FU 500 mg/m2</td>
<td class="gt_row gt_left gt_striped" headers="Neoadjuvant vs Adjuvant CRT  Radiation Type" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Long-course</td>
<td class="gt_row gt_left gt_striped" headers="Neoadjuvant vs Adjuvant CRT  Primary Outcome" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">OS</td>
<td class="gt_row gt_left gt_striped" headers="Neoadjuvant vs Adjuvant CRT  Key Findings" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Pre-op CRT ↓ local recurrence (7% vs 11%), ↓ toxicity, ↑ sphincter-preserving (39% vs. 19%)</td>
</tr>
<tr class="odd">
<td class="gt_row gt_left" headers="Neoadjuvant vs Adjuvant CRT  Study" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;"><p>NSABP R-03</p></td>
<td class="gt_row gt_right" headers="Neoadjuvant vs Adjuvant CRT  Year" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">2004</td>
<td class="gt_row gt_left" headers="Neoadjuvant vs Adjuvant CRT  Tumor characteristics" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">T3–T4 or N+</td>
<td class="gt_row gt_left" headers="Neoadjuvant vs Adjuvant CRT  Tumor location" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">≤ 15 cm from anal verge</td>
<td class="gt_row gt_left" headers="Neoadjuvant vs Adjuvant CRT  Age" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
<td class="gt_row gt_left" headers="Neoadjuvant vs Adjuvant CRT  Experimental Arms" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">6× FU 500 mg/m2 + LV 500 mg/m2 → CRT 45Gy/25f + 5,4 Gy Boost to Tumor bed → TME → 6× FU 500 mg/m2 + LV 500 mg/m2</td>
<td class="gt_row gt_left" headers="Neoadjuvant vs Adjuvant CRT  standard of care" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">TME → 6× FU 500 mg/m2 + LV 500 mg/m2 → CRT 45Gy/25f + 5,4 Gy Boost to Tumor bed → 6× FU 500 mg/m2 + LV 500 mg/m2</td>
<td class="gt_row gt_left" headers="Neoadjuvant vs Adjuvant CRT  Radiation Type" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Long-course</td>
<td class="gt_row gt_left" headers="Neoadjuvant vs Adjuvant CRT  Primary Outcome" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">DFS, OS</td>
<td class="gt_row gt_left" headers="Neoadjuvant vs Adjuvant CRT  Key Findings" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">↑ DFS and ↑ pCR with pre-op CRT, possible ↑OS, ↑ Recurrence free survival</td>
</tr>
<tr class="gt_group_heading_row even">
<td colspan="10" id="Short vs Long Course Radiation" class="gt_group_heading" data-quarto-table-cell-role="th" style="text-align: center; color: #FF0000; font-weight: bold;" scope="colgroup">Short vs Long Course Radiation</td>
</tr>
<tr class="gt_row_group_first odd">
<td class="gt_row gt_left gt_striped" headers="Short vs Long Course Radiation  Study" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;"><p>Dutch TME</p></td>
<td class="gt_row gt_right gt_striped" headers="Short vs Long Course Radiation  Year" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">2001</td>
<td class="gt_row gt_left gt_striped" headers="Short vs Long Course Radiation  Tumor characteristics" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Resectable T1–T3</td>
<td class="gt_row gt_left gt_striped" headers="Short vs Long Course Radiation  Tumor location" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">≤ 15 cm from anal verge</td>
<td class="gt_row gt_left gt_striped" headers="Short vs Long Course Radiation  Age" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">26-88, 23-92</td>
<td class="gt_row gt_left gt_striped" headers="Short vs Long Course Radiation  Experimental Arms" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">SCRT → TME</td>
<td class="gt_row gt_left gt_striped" headers="Short vs Long Course Radiation  standard of care" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">TME alone</td>
<td class="gt_row gt_left gt_striped" headers="Short vs Long Course Radiation  Radiation Type" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Short-course</td>
<td class="gt_row gt_left gt_striped" headers="Short vs Long Course Radiation  Primary Outcome" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Local recurrence</td>
<td class="gt_row gt_left gt_striped" headers="Short vs Long Course Radiation  Key Findings" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">↓ recurrence 2,4% vs 8,2%</td>
</tr>
<tr class="even">
<td class="gt_row gt_left" headers="Short vs Long Course Radiation  Study" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;"><p>Polish Trial</p></td>
<td class="gt_row gt_right" headers="Short vs Long Course Radiation  Year" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">2006</td>
<td class="gt_row gt_left" headers="Short vs Long Course Radiation  Tumor characteristics" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">cT3/T4</td>
<td class="gt_row gt_left" headers="Short vs Long Course Radiation  Tumor location" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">mid</td>
<td class="gt_row gt_left" headers="Short vs Long Course Radiation  Age" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">NA</td>
<td class="gt_row gt_left" headers="Short vs Long Course Radiation  Experimental Arms" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">SCRT → 7d → TME ± 4 mo of bolus 5-fluorouracil and leucovorin</td>
<td class="gt_row gt_left" headers="Short vs Long Course Radiation  standard of care" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">CRT 50,4 Gy/28f → 4-6 wks → TME ± 4 mo of bolus 5-fluorouracil and leucovorin</td>
<td class="gt_row gt_left" headers="Short vs Long Course Radiation  Radiation Type" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Short vs Long-course</td>
<td class="gt_row gt_left" headers="Short vs Long Course Radiation  Primary Outcome" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">sphincter preservation</td>
<td class="gt_row gt_left" headers="Short vs Long Course Radiation  Key Findings" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">sphincter preservation =, CRT ↑ pCR (16% vs 1%), better downstaging, no OS difference</td>
</tr>
<tr class="odd">
<td class="gt_row gt_left gt_striped" headers="Short vs Long Course Radiation  Study" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;"><p>TROG 01.04</p></td>
<td class="gt_row gt_right gt_striped" headers="Short vs Long Course Radiation  Year" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">2012</td>
<td class="gt_row gt_left gt_striped" headers="Short vs Long Course Radiation  Tumor characteristics" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">T3, N0–1</td>
<td class="gt_row gt_left gt_striped" headers="Short vs Long Course Radiation  Tumor location" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">mid-low</td>
<td class="gt_row gt_left gt_striped" headers="Short vs Long Course Radiation  Age" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">26-82</td>
<td class="gt_row gt_left gt_striped" headers="Short vs Long Course Radiation  Experimental Arms" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">SCRT → 3-7d → TME → 6× 5FU 425 mg/m2,folinic acid 20 mg/m2</td>
<td class="gt_row gt_left gt_striped" headers="Short vs Long Course Radiation  standard of care" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">CRT 50,4Gy → 4-6 wks → TME → 4× 5FU 425 mg/m2,folinic acid 20 mg/m2</td>
<td class="gt_row gt_left gt_striped" headers="Short vs Long Course Radiation  Radiation Type" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Short vs Long-course</td>
<td class="gt_row gt_left gt_striped" headers="Short vs Long Course Radiation  Primary Outcome" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">3-year Local recurrence</td>
<td class="gt_row gt_left gt_striped" headers="Short vs Long Course Radiation  Key Findings" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">OS=, Local recurrence 7,5% vs 4,4% not significant</td>
</tr>
<tr class="even">
<td class="gt_row gt_left" headers="Short vs Long Course Radiation  Study" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;"><p>STELLAR</p></td>
<td class="gt_row gt_right" headers="Short vs Long Course Radiation  Year" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">2022</td>
<td class="gt_row gt_left" headers="Short vs Long Course Radiation  Tumor characteristics" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">cT3/T4 and/or N+</td>
<td class="gt_row gt_left" headers="Short vs Long Course Radiation  Tumor location" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">mid-low</td>
<td class="gt_row gt_left" headers="Short vs Long Course Radiation  Age" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">18-70</td>
<td class="gt_row gt_left" headers="Short vs Long Course Radiation  Experimental Arms" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">SCRT→ 4× CAPOX → 4-6 wks → TME → 2× CAPOX</td>
<td class="gt_row gt_left" headers="Short vs Long Course Radiation  standard of care" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">CRT 50,4Gy/28f → 6-8 wks → TME → 6× CAPOX</td>
<td class="gt_row gt_left" headers="Short vs Long Course Radiation  Radiation Type" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Short vs Long-course</td>
<td class="gt_row gt_left" headers="Short vs Long Course Radiation  Primary Outcome" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">DFS</td>
<td class="gt_row gt_left" headers="Short vs Long Course Radiation  Key Findings" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">DSF =; ↓ toxicity</td>
</tr>
<tr class="gt_group_heading_row odd">
<td colspan="10" id="Total Neoadjuvant Therapy" class="gt_group_heading" data-quarto-table-cell-role="th" style="text-align: center; color: #FF0000; font-weight: bold;" scope="colgroup">Total Neoadjuvant Therapy</td>
</tr>
<tr class="gt_row_group_first even">
<td class="gt_row gt_left gt_striped" headers="Total Neoadjuvant Therapy  Study" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;"><p>RAPIDO</p></td>
<td class="gt_row gt_right gt_striped" headers="Total Neoadjuvant Therapy  Year" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">2020</td>
<td class="gt_row gt_left gt_striped" headers="Total Neoadjuvant Therapy  Tumor characteristics" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">T4a/b, N2, EMVI+, CRM+</td>
<td class="gt_row gt_left gt_striped" headers="Total Neoadjuvant Therapy  Tumor location" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">&lt; 16 cm from anal verge</td>
<td class="gt_row gt_left gt_striped" headers="Total Neoadjuvant Therapy  Age" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">31–83</td>
<td class="gt_row gt_left gt_striped" headers="Total Neoadjuvant Therapy  Experimental Arms" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">SCRT → 6× CAPOX / 9× FOLFOX4 → 2-4 wk → TME</td>
<td class="gt_row gt_left gt_striped" headers="Total Neoadjuvant Therapy  standard of care" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">CRT 50,4Gy/28f or 50Gy/25f, → 6-8 wks → TME ± 8× CAPOX/12× FOLFOX4</td>
<td class="gt_row gt_left gt_striped" headers="Total Neoadjuvant Therapy  Radiation Type" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Short/Long-course</td>
<td class="gt_row gt_left gt_striped" headers="Total Neoadjuvant Therapy  Primary Outcome" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">3-year disease-related treatment failure</td>
<td class="gt_row gt_left gt_striped" headers="Total Neoadjuvant Therapy  Key Findings" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">↓ Disease-related treatment failure (24% vs 30%), ↓ distant mets, ↑ pCR (28% vs 14%)</td>
</tr>
<tr class="odd">
<td class="gt_row gt_left" headers="Total Neoadjuvant Therapy  Study" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;"><p>PRODIGE-23</p></td>
<td class="gt_row gt_right" headers="Total Neoadjuvant Therapy  Year" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">2021</td>
<td class="gt_row gt_left" headers="Total Neoadjuvant Therapy  Tumor characteristics" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">cT3 or cT4 M0</td>
<td class="gt_row gt_left" headers="Total Neoadjuvant Therapy  Tumor location" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">&lt; 16 cm from anal verge</td>
<td class="gt_row gt_left" headers="Total Neoadjuvant Therapy  Age" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">18–75</td>
<td class="gt_row gt_left" headers="Total Neoadjuvant Therapy  Experimental Arms" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">FOLFIRINOX ×6 → CRT 50Gy/25f → TME → 6× FOLFOX6 or 4× capecitabine ×4</td>
<td class="gt_row gt_left" headers="Total Neoadjuvant Therapy  standard of care" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">CRT 50Gy/25f → TME → 12× FOLFOX6 or 8× capecitabine</td>
<td class="gt_row gt_left" headers="Total Neoadjuvant Therapy  Radiation Type" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Long-course</td>
<td class="gt_row gt_left" headers="Total Neoadjuvant Therapy  Primary Outcome" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">DFS</td>
<td class="gt_row gt_left" headers="Total Neoadjuvant Therapy  Key Findings" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">↑ DFS, ↑ pCR (28% vs 12%), ↓ distant mets</td>
</tr>
<tr class="even">
<td class="gt_row gt_left gt_striped" headers="Total Neoadjuvant Therapy  Study" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;"><p>OPRA</p></td>
<td class="gt_row gt_right gt_striped" headers="Total Neoadjuvant Therapy  Year" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">2022</td>
<td class="gt_row gt_left gt_striped" headers="Total Neoadjuvant Therapy  Tumor characteristics" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Stage II–III</td>
<td class="gt_row gt_left gt_striped" headers="Total Neoadjuvant Therapy  Tumor location" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">mid–low</td>
<td class="gt_row gt_left gt_striped" headers="Total Neoadjuvant Therapy  Age" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">IQR 51-68</td>
<td class="gt_row gt_left gt_striped" headers="Total Neoadjuvant Therapy  Experimental Arms" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">8× FOLFOX or 5× CAPEOX → CRT 1,8 to 50-56 Gy</td>
<td class="gt_row gt_left gt_striped" headers="Total Neoadjuvant Therapy  standard of care" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">CRT 1,8 to 50-56 Gy → 8× FOLFOX or 5× CAPEOX</td>
<td class="gt_row gt_left gt_striped" headers="Total Neoadjuvant Therapy  Radiation Type" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">Long-course</td>
<td class="gt_row gt_left gt_striped" headers="Total Neoadjuvant Therapy  Primary Outcome" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">DSF, Organ preservation</td>
<td class="gt_row gt_left gt_striped" headers="Total Neoadjuvant Therapy  Key Findings" style="text-align: center; font-family: 'Source Sans Pro'; font-weight: 400;">CRT-first→ better organ preservation (53% vs 41%), DFS =</td>
</tr>
</tbody><tfoot class="gt_sourcenotes">
<tr class="odd">
<td colspan="10" class="gt_sourcenote" style="text-align: center;">cCR = clinical complete response, CRT = chemoradiotherapy, TME = Total mesorectal excision, LV = Leucovorin, OS = Overall survival, DSF = disease-free survival, pCR = pathological complete response, SCRT = Short-course radiation therapy (25 Gy/5f).</td>
</tr>
</tfoot>

</table>

</div>
</div>
</div>
</section>
<section id="literatur" class="level1">




</section>

<div id="quarto-appendix" class="default"><section class="quarto-appendix-contents" role="doc-bibliography" id="quarto-bibliography"><h2 class="anchored quarto-appendix-heading">Literatur</h2><div id="refs" class="references csl-bib-body" role="list">
<div id="ref-DeutscheKrebsgesellschaftEtAl2019" class="csl-entry" role="listitem">
<div class="csl-left-margin">1. </div><div class="csl-right-inline">Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF. <span>Leitlinienprogramm Onkologie: S3-Leitlinie Kolorektales Karzinom, AWMF Registrierungsnummer: 021/007OL</span>. Published online 2019.</div>
</div>
<div id="ref-GallerEtAl2011" class="csl-entry" role="listitem">
<div class="csl-left-margin">2. </div><div class="csl-right-inline">Galler AS, Petrelli NJ, Shakamuri SP. Rectal cancer surgery: <span>A</span> brief history. <em>Surgical Oncology</em>. 2011;20(4):223-230. doi:<a href="https://doi.org/10.1016/j.suronc.2010.01.001">10.1016/j.suronc.2010.01.001</a></div>
</div>
<div id="ref-HealdRyall1986" class="csl-entry" role="listitem">
<div class="csl-left-margin">3. </div><div class="csl-right-inline">Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. <em>Lancet (London, England)</em>. 1986;1(8496):1479-1482. doi:<a href="https://doi.org/10.1016/s0140-6736(86)91510-2">10.1016/s0140-6736(86)91510-2</a></div>
</div>
<div id="ref-DeschnerEtAl2021" class="csl-entry" role="listitem">
<div class="csl-left-margin">4. </div><div class="csl-right-inline">Deschner BW, VanderWalde NA, Grothey A, Shibata D. Evolution and <span>Current Status</span> of the <span>Multidisciplinary Management</span> of <span>Locally Advanced Rectal Cancer</span>. <em>JCO Oncology Practice</em>. 2021;17(7):383-402. doi:<a href="https://doi.org/10.1200/OP.20.00885">10.1200/OP.20.00885</a></div>
</div>
<div id="ref-GastrointestinalTumorStudyGroup1985" class="csl-entry" role="listitem">
<div class="csl-left-margin">5. </div><div class="csl-right-inline">Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. <em>The New England Journal of Medicine</em>. 1985;312(23):1465-1472. doi:<a href="https://doi.org/10.1056/NEJM198506063122301">10.1056/NEJM198506063122301</a></div>
</div>
<div id="ref-SwedishRectalCancerTrial1997" class="csl-entry" role="listitem">
<div class="csl-left-margin">6. </div><div class="csl-right-inline">Swedish Rectal Cancer Trial. Improved <span>Survival</span> with <span>Preoperative Radiotherapy</span> in <span>Resectable Rectal Cancer</span>. <em>New England Journal of Medicine</em>. 1997;336(14):980-987. doi:<a href="https://doi.org/10.1056/NEJM199704033361402">10.1056/NEJM199704033361402</a></div>
</div>
<div id="ref-SauerEtAl2004" class="csl-entry" role="listitem">
<div class="csl-left-margin">7. </div><div class="csl-right-inline">Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. <em>The New England Journal of Medicine</em>. 2004;351(17):1731-1740. doi:<a href="https://doi.org/10.1056/NEJMoa040694">10.1056/NEJMoa040694</a></div>
</div>
<div id="ref-IVEtAl2022" class="csl-entry" role="listitem">
<div class="csl-left-margin">8. </div><div class="csl-right-inline">IV AA, Koprowski MA, Nabavizadeh N, Tsikitis VL. The evolution of rectal cancer treatment: The journey to total neoadjuvant therapy and organ preservation. <em>Annals of Gastroenterology</em>. 2022;35(3):226-233. doi:<a href="https://doi.org/10.20524/aog.2022.0712">10.20524/aog.2022.0712</a></div>
</div>
<div id="ref-ErlandssonEtAl2017" class="csl-entry" role="listitem">
<div class="csl-left-margin">9. </div><div class="csl-right-inline">Erlandsson J, Holm T, Pettersson D, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (<span>Stockholm III</span>): A multicentre, randomised, non-blinded, phase 3, non-inferiority trial. <em>The Lancet Oncology</em>. 2017;18(3):336-346. doi:<a href="https://doi.org/10.1016/S1470-2045(17)30086-4">10.1016/S1470-2045(17)30086-4</a></div>
</div>
<div id="ref-BahadoerEtAl2021" class="csl-entry" role="listitem">
<div class="csl-left-margin">10. </div><div class="csl-right-inline">Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (<span>TME</span>) versus preoperative chemoradiotherapy, <span>TME</span>, and optional adjuvant chemotherapy in locally advanced rectal cancer (<span>RAPIDO</span>): A randomised, open-label, phase 3 trial. <em>The Lancet Oncology</em>. 2021;22(1):29-42. doi:<a href="https://doi.org/10.1016/S1470-2045(20)30555-6">10.1016/S1470-2045(20)30555-6</a></div>
</div>
<div id="ref-ConroyEtAl2021" class="csl-entry" role="listitem">
<div class="csl-left-margin">11. </div><div class="csl-right-inline">Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with <span>FOLFIRINOX</span> and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (<span>UNICANCER-PRODIGE</span> 23): A multicentre, randomised, open-label, phase 3 trial. <em>The Lancet Oncology</em>. 2021;22(5):702-715. doi:<a href="https://doi.org/10.1016/S1470-2045(21)00079-6">10.1016/S1470-2045(21)00079-6</a></div>
</div>
<div id="ref-Garcia-AguilarEtAl2022" class="csl-entry" role="listitem">
<div class="csl-left-margin">12. </div><div class="csl-right-inline">Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ <span>Preservation</span> in <span>Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy</span>. <em>Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology</em>. 2022;40(23):2546-2556. doi:<a href="https://doi.org/10.1200/JCO.22.00032">10.1200/JCO.22.00032</a></div>
</div>
<div id="ref-CercekEtAl2022" class="csl-entry" role="listitem">
<div class="csl-left-margin">13. </div><div class="csl-right-inline">Cercek A, Lumish M, Sinopoli J, et al. <span>PD-1 Blockade</span> in <span>Mismatch Repair</span>–<span>Deficient</span>, <span>Locally Advanced Rectal Cancer</span>. <em>New England Journal of Medicine</em>. 2022;386(25):2363-2376. doi:<a href="https://doi.org/10.1056/NEJMoa2201445">10.1056/NEJMoa2201445</a></div>
</div>
<div id="ref-Aerzteblatt2012" class="csl-entry" role="listitem">
<div class="csl-left-margin">14. </div><div class="csl-right-inline">Ärzteblatt DÄG Redaktion Deutsches. <span>Zostex: T<span>ö</span>dliche Wechselwirkung mit 5-Fluoropyrimidinen</span>. <em>Deutsches <span>Ä</span>rzteblatt</em>. Published online September 2012.</div>
</div>
<div id="ref-DGHO2020" class="csl-entry" role="listitem">
<div class="csl-left-margin">15. </div><div class="csl-right-inline">DGHO. <span>Dihydropyrimidin-Dehydrogenase (DPD) – Testung vor Einsatz von 5-Fluorouracil, Capecitabin und Tegafur</span>. Published online February 2020.</div>
</div>
<div id="ref-2020" class="csl-entry" role="listitem">
<div class="csl-left-margin">16. </div><div class="csl-right-inline"><span>DPD-Testung vor dem Einsatz 5-FU-h<span>ä</span>ltiger Chemotherapie</span>. <em>SPECTRUM Onkologie</em>. Published online May 2020.</div>
</div>
<div id="ref-NationalComprehensiveCancerNetwork2025a" class="csl-entry" role="listitem">
<div class="csl-left-margin">17. </div><div class="csl-right-inline">National Comprehensive Cancer Network. <span>NCCN Clinical Practice Guidelines</span> in <span>Oncology</span>: <span>Rectal Cancer</span> (<span>Version</span> 2.2025). Published online March 2025.</div>
</div>
<div id="ref-Ralf-DieterHofheinzEtAl2025" class="csl-entry" role="listitem">
<div class="csl-left-margin">18. </div><div class="csl-right-inline">Ralf-Dieter Hofheinz, Dirk Arnold, Markus Borner, et al. <span>ONKOPEDIA</span> - <span>Leitlinie Rektumkarzinom</span>. Published online February 2025.</div>
</div>
<div id="ref-BujkoEtAl2006" class="csl-entry" role="listitem">
<div class="csl-left-margin">19. </div><div class="csl-right-inline">Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. <em>The British Journal of Surgery</em>. 2006;93(10):1215-1223. doi:<a href="https://doi.org/10.1002/bjs.5506">10.1002/bjs.5506</a></div>
</div>
<div id="ref-JinEtAl2022" class="csl-entry" role="listitem">
<div class="csl-left-margin">20. </div><div class="csl-right-inline">Jin J, Tang Y, Hu C, et al. Multicenter, <span>Randomized</span>, <span>Phase III Trial</span> of <span>Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy</span> in <span>Locally Advanced Rectal Cancer</span> (<span>STELLAR</span>). <em>Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology</em>. 2022;40(15):1681-1692. doi:<a href="https://doi.org/10.1200/JCO.21.01667">10.1200/JCO.21.01667</a></div>
</div>
<div id="ref-FokasEtAl2019" class="csl-entry" role="listitem">
<div class="csl-left-margin">21. </div><div class="csl-right-inline">Fokas E, Allgäuer M, Polat B, et al. Randomized <span>Phase II Trial</span> of <span>Chemoradiotherapy Plus Induction</span> or <span>Consolidation Chemotherapy</span> as <span>Total Neoadjuvant Therapy</span> for <span>Locally Advanced Rectal Cancer</span>: <span>CAO</span>/<span>ARO</span>/<span>AIO-12</span>. <em>Journal of Clinical Oncology</em>. 2019;37(34):3212-3222. doi:<a href="https://doi.org/10.1200/JCO.19.00308">10.1200/JCO.19.00308</a></div>
</div>
<div id="ref-SaraEtAl2018" class="csl-entry" role="listitem">
<div class="csl-left-margin">22. </div><div class="csl-right-inline">Sara JD, Kaur J, Khodadadi R, et al. 5-fluorouracil and cardiotoxicity: A review. <em>Therapeutic Advances in Medical Oncology</em>. 2018;10:1758835918780140. doi:<a href="https://doi.org/10.1177/1758835918780140">10.1177/1758835918780140</a></div>
</div>
</div></section></div></main> <!-- /main -->
<script id="quarto-html-after-body" type="application/javascript">
  window.document.addEventListener("DOMContentLoaded", function (event) {
    const icon = "";
    const anchorJS = new window.AnchorJS();
    anchorJS.options = {
      placement: 'right',
      icon: icon
    };
    anchorJS.add('.anchored');
    const isCodeAnnotation = (el) => {
      for (const clz of el.classList) {
        if (clz.startsWith('code-annotation-')) {                     
          return true;
        }
      }
      return false;
    }
    const onCopySuccess = function(e) {
      // button target
      const button = e.trigger;
      // don't keep focus
      button.blur();
      // flash "checked"
      button.classList.add('code-copy-button-checked');
      var currentTitle = button.getAttribute("title");
      button.setAttribute("title", "Copied!");
      let tooltip;
      if (window.bootstrap) {
        button.setAttribute("data-bs-toggle", "tooltip");
        button.setAttribute("data-bs-placement", "left");
        button.setAttribute("data-bs-title", "Copied!");
        tooltip = new bootstrap.Tooltip(button, 
          { trigger: "manual", 
            customClass: "code-copy-button-tooltip",
            offset: [0, -8]});
        tooltip.show();    
      }
      setTimeout(function() {
        if (tooltip) {
          tooltip.hide();
          button.removeAttribute("data-bs-title");
          button.removeAttribute("data-bs-toggle");
          button.removeAttribute("data-bs-placement");
        }
        button.setAttribute("title", currentTitle);
        button.classList.remove('code-copy-button-checked');
      }, 1000);
      // clear code selection
      e.clearSelection();
    }
    const getTextToCopy = function(trigger) {
        const codeEl = trigger.previousElementSibling.cloneNode(true);
        for (const childEl of codeEl.children) {
          if (isCodeAnnotation(childEl)) {
            childEl.remove();
          }
        }
        return codeEl.innerText;
    }
    const clipboard = new window.ClipboardJS('.code-copy-button:not([data-in-quarto-modal])', {
      text: getTextToCopy
    });
    clipboard.on('success', onCopySuccess);
    if (window.document.getElementById('quarto-embedded-source-code-modal')) {
      const clipboardModal = new window.ClipboardJS('.code-copy-button[data-in-quarto-modal]', {
        text: getTextToCopy,
        container: window.document.getElementById('quarto-embedded-source-code-modal')
      });
      clipboardModal.on('success', onCopySuccess);
    }
      var localhostRegex = new RegExp(/^(?:http|https):\/\/localhost\:?[0-9]*\//);
      var mailtoRegex = new RegExp(/^mailto:/);
        var filterRegex = new RegExp("https:\/\/MD-Torres\.github\.io\/mtra-schule\/");
      var isInternal = (href) => {
          return filterRegex.test(href) || localhostRegex.test(href) || mailtoRegex.test(href);
      }
      // Inspect non-navigation links and adorn them if external
     var links = window.document.querySelectorAll('a[href]:not(.nav-link):not(.navbar-brand):not(.toc-action):not(.sidebar-link):not(.sidebar-item-toggle):not(.pagination-link):not(.no-external):not([aria-hidden]):not(.dropdown-item):not(.quarto-navigation-tool):not(.about-link)');
      for (var i=0; i<links.length; i++) {
        const link = links[i];
        if (!isInternal(link.href)) {
          // undo the damage that might have been done by quarto-nav.js in the case of
          // links that we want to consider external
          if (link.dataset.originalHref !== undefined) {
            link.href = link.dataset.originalHref;
          }
        }
      }
    function tippyHover(el, contentFn, onTriggerFn, onUntriggerFn) {
      const config = {
        allowHTML: true,
        maxWidth: 500,
        delay: 100,
        arrow: false,
        appendTo: function(el) {
            return el.parentElement;
        },
        interactive: true,
        interactiveBorder: 10,
        theme: 'quarto',
        placement: 'bottom-start',
      };
      if (contentFn) {
        config.content = contentFn;
      }
      if (onTriggerFn) {
        config.onTrigger = onTriggerFn;
      }
      if (onUntriggerFn) {
        config.onUntrigger = onUntriggerFn;
      }
      window.tippy(el, config); 
    }
    const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
    for (var i=0; i<noterefs.length; i++) {
      const ref = noterefs[i];
      tippyHover(ref, function() {
        // use id or data attribute instead here
        let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
        try { href = new URL(href).hash; } catch {}
        const id = href.replace(/^#\/?/, "");
        const note = window.document.getElementById(id);
        if (note) {
          return note.innerHTML;
        } else {
          return "";
        }
      });
    }
    const xrefs = window.document.querySelectorAll('a.quarto-xref');
    const processXRef = (id, note) => {
      // Strip column container classes
      const stripColumnClz = (el) => {
        el.classList.remove("page-full", "page-columns");
        if (el.children) {
          for (const child of el.children) {
            stripColumnClz(child);
          }
        }
      }
      stripColumnClz(note)
      if (id === null || id.startsWith('sec-')) {
        // Special case sections, only their first couple elements
        const container = document.createElement("div");
        if (note.children && note.children.length > 2) {
          container.appendChild(note.children[0].cloneNode(true));
          for (let i = 1; i < note.children.length; i++) {
            const child = note.children[i];
            if (child.tagName === "P" && child.innerText === "") {
              continue;
            } else {
              container.appendChild(child.cloneNode(true));
              break;
            }
          }
          if (window.Quarto?.typesetMath) {
            window.Quarto.typesetMath(container);
          }
          return container.innerHTML
        } else {
          if (window.Quarto?.typesetMath) {
            window.Quarto.typesetMath(note);
          }
          return note.innerHTML;
        }
      } else {
        // Remove any anchor links if they are present
        const anchorLink = note.querySelector('a.anchorjs-link');
        if (anchorLink) {
          anchorLink.remove();
        }
        if (window.Quarto?.typesetMath) {
          window.Quarto.typesetMath(note);
        }
        if (note.classList.contains("callout")) {
          return note.outerHTML;
        } else {
          return note.innerHTML;
        }
      }
    }
    for (var i=0; i<xrefs.length; i++) {
      const xref = xrefs[i];
      tippyHover(xref, undefined, function(instance) {
        instance.disable();
        let url = xref.getAttribute('href');
        let hash = undefined; 
        if (url.startsWith('#')) {
          hash = url;
        } else {
          try { hash = new URL(url).hash; } catch {}
        }
        if (hash) {
          const id = hash.replace(/^#\/?/, "");
          const note = window.document.getElementById(id);
          if (note !== null) {
            try {
              const html = processXRef(id, note.cloneNode(true));
              instance.setContent(html);
            } finally {
              instance.enable();
              instance.show();
            }
          } else {
            // See if we can fetch this
            fetch(url.split('#')[0])
            .then(res => res.text())
            .then(html => {
              const parser = new DOMParser();
              const htmlDoc = parser.parseFromString(html, "text/html");
              const note = htmlDoc.getElementById(id);
              if (note !== null) {
                const html = processXRef(id, note);
                instance.setContent(html);
              } 
            }).finally(() => {
              instance.enable();
              instance.show();
            });
          }
        } else {
          // See if we can fetch a full url (with no hash to target)
          // This is a special case and we should probably do some content thinning / targeting
          fetch(url)
          .then(res => res.text())
          .then(html => {
            const parser = new DOMParser();
            const htmlDoc = parser.parseFromString(html, "text/html");
            const note = htmlDoc.querySelector('main.content');
            if (note !== null) {
              // This should only happen for chapter cross references
              // (since there is no id in the URL)
              // remove the first header
              if (note.children.length > 0 && note.children[0].tagName === "HEADER") {
                note.children[0].remove();
              }
              const html = processXRef(null, note);
              instance.setContent(html);
            } 
          }).finally(() => {
            instance.enable();
            instance.show();
          });
        }
      }, function(instance) {
      });
    }
        let selectedAnnoteEl;
        const selectorForAnnotation = ( cell, annotation) => {
          let cellAttr = 'data-code-cell="' + cell + '"';
          let lineAttr = 'data-code-annotation="' +  annotation + '"';
          const selector = 'span[' + cellAttr + '][' + lineAttr + ']';
          return selector;
        }
        const selectCodeLines = (annoteEl) => {
          const doc = window.document;
          const targetCell = annoteEl.getAttribute("data-target-cell");
          const targetAnnotation = annoteEl.getAttribute("data-target-annotation");
          const annoteSpan = window.document.querySelector(selectorForAnnotation(targetCell, targetAnnotation));
          const lines = annoteSpan.getAttribute("data-code-lines").split(",");
          const lineIds = lines.map((line) => {
            return targetCell + "-" + line;
          })
          let top = null;
          let height = null;
          let parent = null;
          if (lineIds.length > 0) {
              //compute the position of the single el (top and bottom and make a div)
              const el = window.document.getElementById(lineIds[0]);
              top = el.offsetTop;
              height = el.offsetHeight;
              parent = el.parentElement.parentElement;
            if (lineIds.length > 1) {
              const lastEl = window.document.getElementById(lineIds[lineIds.length - 1]);
              const bottom = lastEl.offsetTop + lastEl.offsetHeight;
              height = bottom - top;
            }
            if (top !== null && height !== null && parent !== null) {
              // cook up a div (if necessary) and position it 
              let div = window.document.getElementById("code-annotation-line-highlight");
              if (div === null) {
                div = window.document.createElement("div");
                div.setAttribute("id", "code-annotation-line-highlight");
                div.style.position = 'absolute';
                parent.appendChild(div);
              }
              div.style.top = top - 2 + "px";
              div.style.height = height + 4 + "px";
              div.style.left = 0;
              let gutterDiv = window.document.getElementById("code-annotation-line-highlight-gutter");
              if (gutterDiv === null) {
                gutterDiv = window.document.createElement("div");
                gutterDiv.setAttribute("id", "code-annotation-line-highlight-gutter");
                gutterDiv.style.position = 'absolute';
                const codeCell = window.document.getElementById(targetCell);
                const gutter = codeCell.querySelector('.code-annotation-gutter');
                gutter.appendChild(gutterDiv);
              }
              gutterDiv.style.top = top - 2 + "px";
              gutterDiv.style.height = height + 4 + "px";
            }
            selectedAnnoteEl = annoteEl;
          }
        };
        const unselectCodeLines = () => {
          const elementsIds = ["code-annotation-line-highlight", "code-annotation-line-highlight-gutter"];
          elementsIds.forEach((elId) => {
            const div = window.document.getElementById(elId);
            if (div) {
              div.remove();
            }
          });
          selectedAnnoteEl = undefined;
        };
          // Handle positioning of the toggle
      window.addEventListener(
        "resize",
        throttle(() => {
          elRect = undefined;
          if (selectedAnnoteEl) {
            selectCodeLines(selectedAnnoteEl);
          }
        }, 10)
      );
      function throttle(fn, ms) {
      let throttle = false;
      let timer;
        return (...args) => {
          if(!throttle) { // first call gets through
              fn.apply(this, args);
              throttle = true;
          } else { // all the others get throttled
              if(timer) clearTimeout(timer); // cancel #2
              timer = setTimeout(() => {
                fn.apply(this, args);
                timer = throttle = false;
              }, ms);
          }
        };
      }
        // Attach click handler to the DT
        const annoteDls = window.document.querySelectorAll('dt[data-target-cell]');
        for (const annoteDlNode of annoteDls) {
          annoteDlNode.addEventListener('click', (event) => {
            const clickedEl = event.target;
            if (clickedEl !== selectedAnnoteEl) {
              unselectCodeLines();
              const activeEl = window.document.querySelector('dt[data-target-cell].code-annotation-active');
              if (activeEl) {
                activeEl.classList.remove('code-annotation-active');
              }
              selectCodeLines(clickedEl);
              clickedEl.classList.add('code-annotation-active');
            } else {
              // Unselect the line
              unselectCodeLines();
              clickedEl.classList.remove('code-annotation-active');
            }
          });
        }
    const findCites = (el) => {
      const parentEl = el.parentElement;
      if (parentEl) {
        const cites = parentEl.dataset.cites;
        if (cites) {
          return {
            el,
            cites: cites.split(' ')
          };
        } else {
          return findCites(el.parentElement)
        }
      } else {
        return undefined;
      }
    };
    var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
    for (var i=0; i<bibliorefs.length; i++) {
      const ref = bibliorefs[i];
      const citeInfo = findCites(ref);
      if (citeInfo) {
        tippyHover(citeInfo.el, function() {
          var popup = window.document.createElement('div');
          citeInfo.cites.forEach(function(cite) {
            var citeDiv = window.document.createElement('div');
            citeDiv.classList.add('hanging-indent');
            citeDiv.classList.add('csl-entry');
            var biblioDiv = window.document.getElementById('ref-' + cite);
            if (biblioDiv) {
              citeDiv.innerHTML = biblioDiv.innerHTML;
            }
            popup.appendChild(citeDiv);
          });
          return popup.innerHTML;
        });
      }
    }
  });
  </script>
</div> <!-- /content -->




</body></html>